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CHAPTER I 
 
INTRODUCTION 
 
Chloride regulation in GABAergic signaling and inhibitory neurotransmission 
The regulation of intracellular neuronal chloride is essential to proper 
neurotransmission.  In the nervous system, excitatory neurotransmitters generate action 
potentials by causing a depolarization of the neuronal membrane potential.  Inhibitory 
neurotransmission propagated by the neurotransmitters glycine and GABA are required 
to balance and fine tune this system.  GABA is the predominant inhibitory 
neurotransmitter in the adult nervous system, acting primarily through the ionotropic 
GABAA receptors.  The GABAA receptor primarily transports chloride ions, with some 
bicarbonate ions transported through the channel as well.  When GABA stimulates the 
GABAA receptor, an inhibitory response is generated by the hyperpolarization caused by 
chloride ions moving into the cell due to the low intracellular chloride concentration.  
Thus, it is this low intracellular chloride concentration which allows GABA to have an 
inhibitory effect.  When internal chloride concentrations are higher than the external 
milieu, GABA instead acts as an excitatory neurotransmitter.   
The regulation of intracellular chloride concentration in neurons is governed 
primarily by a family of ion cotransporters known as the cation chloride cotransporters, 
or CCCs.   
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Cation-chloride family of transporters  
Seven CCCs have been identified: one Na+-Cl- cotransporter (NCC), two Na+-
K+-Cl- cotransporters (NKCC1 and NKCC2), and four K+-Cl- cotransporters (KCC1-4) 
(Figure 1).  The Na-Cl cotransporter is inhibited by thiazide diuretics, whereas the Na-K-
2Cl and the K-Cl cotransporters are inhibited by the loop diuretics bumetanide and 
furosemide. NCC and NKCC2 are renal-specific, while the remaining five cotransporters 
are all found in the brain (Delpire, 2000). Furosemide and bumetanide are loop diuretics 
that target the cation-chloride cotransporters, but they are very unspecific. The KCC 
family includes four isoforms (KCC1-4). They all share an approximate 30% amino acid 
identity to other members of the CCC family. KCCs transport K+ to Cl- in a  1:1 ratio, 
allowing for electroneutral transport (Lauf et al., 1992; Jennings and Adame, 2001). All 
KCCs are sensitive to changes in cell volume and are activated by cell swelling (Gillen et 
al., 1996; Hiki et al., 1999; Mount et al., 1999; Race et al., 1999). Upon cell swelling, 
KCCs extrude K+ and Cl- ions from the cell, returning cell volume to control values.  
KCC1 is a ubiquitously expressed protein, with a ‘housekeeping’ role in cell volume 
maintenance and regulation. KCC3 and KCC4 are widely but not universally expressed. 
They are both found predominantly in kidney, heart, skeletal muscle and brain (Hiki et 
al., 1999; Mount et al., 1999; Race et al., 1999; Pearson et al., 2001).  
KCC2
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NKCC1
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K
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-
Na
+
2Cl
-
Na
+
Cl
-
K
+
Chr.18,32
Chr.2,69.5
Chr.2
Chr.8.53
Chr.13
Chr.2
20q12
5q15
16q22
15q14
5q23
15q21
16q13
Chr.8,45
Figure 1. Tree of cation-chloride cotransporter family.
Homology tree of the cation chloride cotransporter (CCC) family. There are
four potassium chloride cotrasnporter (KCC) isoforms, with the greatest
similarity between KCC1 and KCC3, and KCC2 and KCC4. The only sodium
chloride cotransporter (NCC) and the two isoforms of sodium-potassium-
chloride cotransporters (NKCC1, and NKCC2) are likewise shown. Next to
each isoform, mouse and human chromosome locations are shown. Murine,
upper/blue text; human lower/red text.
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KCC2 background 
Structure  
KCC2 has a high (~67%) amino acid identity to the other KCCs, with the greatest 
homology to KCC4 (Payne et al., 1996; Mount et al., 1999). All members of the CCC 
family have twelve transmembrane domains with cytoplasmic N’ and C’ terminal regions 
(Lauf and Adragna, 2000).  KCCs are set apart from other CCCs by a large predicted 
extracellular loop with 4 putative N-glycosylation sites, present between transmembrane 
domains 5 and 6 (Payne et al., 1996) (Figure 2). The KCCs also have a number of 
putative protein kinase C phosphorylation sites in the C terminus (Payne et al., 1996). 
KCC2 and KCC4 share a tyrosine kinase consensus phosphorylation site in the C’ 
terminus (Payne et al., 1996; Mount et al., 1999). It has been shown that this tyrosine 
residue (Y1087) is critical for KCC2 function, yet amino acid substitutions and 
pharmacological studies show no regulatory role for tyrosine residue phosphorylation 
(Strange et al., 2000). KCC2 has a 34 amino acid region, also located in the carboxyl 
terminus, which is unique from the other KCC isoforms (Payne et al., 1996; Hiki et al., 
1999; Mount et al., 1999). Although there was only known isoform of KCC2 for over a 
decade, we now know there are two isoforms of this cotransporter.  KCC2b, which had 
been first cloned in 1996, is the most prominent and well-studied isoform of the 
transporter -- it is the isoform which has been shown to have very little expression early 
in life, but is upregulated during development.  KCC2b is also the most abundant during 
maturity. Most recently, Uvarov, et al. discovered an alternative promoter and first exon 
located upstream of the previously identified start of KCC2b.  This novel KCC2 isoform, 
KCC2a, differs by 40 amino acids in the N-terminal region.  The KCC2a isoform makes 
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up almost 50% of the low KCC2 levels present after birth, but only 5-10% of the total 
KCC2 in the mature cortex (Uvarov et al., 2007).    
Several reports contribute to the hypothesis that KCC2 likely exists as functional 
homomultimers. NKCC1 has been reported to exist as a dimer (Moore-Hoon and Turner, 
2000) and dominant negative effects by truncated KCC1 coexpressed with wild type 
KCC suggest that the KCCs function as multimers, as well (Casula et al., 2001). Analysis 
of rat brain proteins taken at different ages have also been analyzed by SDS-
PAGE/Western blot in different concentrations of cross-linking and reducing agents.  
This study suggested that oligomerization of KCC2 is age-dependent, with monomeric 
inactive KCC2 present to a small extent in early development, and active homodimers 
present in mature brain (Blaesse et al., 2006).  Yeast two-hybrid and pull-down assays of 
heterologously expressed CCCs have suggested that the KCC isoforms, as well as 
NKCC1, could possibly exist in heteromultimers, although further work needs to be done 
to demonstrate this in vivo and explain its possible physiological role (Simard et al., 
2007). 
Spatial and temporal KCC2 Expression 
KCC2 is unique to all the KCCs in that it is only expressed in neurons. A 
Neuronal Restrictive Silencing Element found in the KCC2 gene is proposed to confer 
neuron-specific KCC2 expression (Karadsheh and Delpire, 2001). Analysis of KCC2 
gene regulation identified several potential transcription factor binding sites in the KCC2 
promoter region.  One of these proposed transcription factors, Early growth response 4 
(Egr4) has been demonstrated in cultured neurons as having a functional effect on KCC2 
transcription (Uvarov et al., 2005; Uvarov et al., 2006).  KCC2 is expressed highly 
Figure 2. Predicted topology of KCC2.
Kyle-Doolittle hydropathy plot analysis of KCC2 predicts a twelve
transmembrane domain protein with intracellular N' and C' terminal tails, as
reported in Payne et al., 1996. A large extracellular loop with four predicted
N-glycosylation sites occurs between transmembrane domains 5 and 6. All
members of the CCC family share this 12 transmembrane domain and
intracellular N' and C' tail structure.
6
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throughout the central nervous system, and enriched in GABAergic and glycinergic 
neurons, including pyramidal neurons of the hippocampus and Purkinje neurons and 
granular cells of the cerebellum, as exemplified in Figure 3 (Payne et al., 1996; Lu et al., 
1999; Williams et al., 1999).  In the granule cell layer of the cerebellum, KCC2 exhibits 
distinct colocalization with the β2/β3-subunits of the GABAA receptor (Williams et al., 
1999).  In terms of subcellular localization, immunolocalization studies in rat cerebellum, 
spinal cord, and hippocampus show that KCC2 is primarily expressed at neuronal soma 
and dendrites (Williams et al., 1999; Gulyas et al., 2001; Hubner et al., 2001).  Although 
KCC2 is closely linked with GABAergic signaling, it is not, however, confined to the 
vicinity of inhibitory synapses. KCC2 shows subcellular localization near excitatory 
synaptic inputs in the adult rat hippocampus, potentially in correlation to the presence of 
extrasynaptic GABAA receptors expressed on the shafts of dendritic spines (Gulyas et al., 
2001). 
  KCC2 expression overlaps with gonadotropin-releasing hormone (GnRH) in 
approximately 35% of GnRH-neurons, and there appears to be sexual dimorphism in 
KCC2 expression during development.  Only females exhibit a gradient of KCC2 
expression in GnRH-cells from the rostral to caudal sides of the brain. Males, however, 
maintain a consistent level of  KCC2 localization (Leupen et al., 2003).  At postnatal day 
15, KCC2 expression in the substantia nigra pars reticulate is significantly lower in male 
rats than female rats.  Electrophysiology experiments using cells from this age and brain 
region show the functional effect of this difference, as application of the GABAA agonist  
A.
B.
C.
D.
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Figure 3. KCC2 expression in the brain. 
Sagittal sections of adult male C57BL/6J mouse brains show KCC2 gene expression 
throughout the brain, by in situ hybridization (A, C) and shown with corresponding 
color map of gene expression (B, D). Insets show position of slices from coronal 
perspective. A, B: position 2000. C, D. position 2400. Images obtained from Allen 
Brain Atlas [Internet].  Seattle (WA): Allen Institute for Brain Science, 2007.  
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muscimol depolarizes male neurons, but hyperpolarizes female neurons (Galanopoulou 
and Moshe, 2003).  Similar differences in KCC2 levels have also been reported in 
neurons of the developing hippocampus and developing hypothalamus (Nunez and 
McCarthy, 2007; Perrot-Sinal et al., 2007)  Such differences between males and females 
are an interesting field of expanded studies, in light of predisposition of males to 
developmental disorders associated with GABA signaling, and male susceptibility to 
brain injury (McCarthy et al., 2002; Galanopoulou and Moshe, 2003). 
KCC2 expression is upregulated throughout development, with the greatest 
expression during adulthood.  Minimal amounts of KCC2 RNA and protein are expressed 
during birth, and it has been recently shown that the isoform which is present is the less-
common KCC2a isoform, as discussed earlier (Lu et al., 1999; Uvarov et al., 2007).   
The upregulation of KCC2 expression is coincident with a change in GABAergic 
responses.  In early development, GABA is an excitatory, depolarizing neurotransmitter.  
GABA signaling later transitions to inhibitory and hyperpolarizing; this the most 
prominent GABAergic effect during adulthood.  The role of KCC2 in GABAergic 
signaling will be discussed later in the introduction. 
  
KCC2 activity and regulation 
Like the other KCCs, KCC2 is an electroneutral cation-chloride cotransporter.  A 
direct estimate of KCC stoichiometry in erythrocytes suggests a 1:1 ratio of K+ ions and  
Cl- ions are transported together across the cell membrane (Jennings and Adame, 2001), 
and numerous electrophysiological experiments likewise indicate that KCC2 function 
does not affect the membrane potential.   This electroneutral stoichiometry makes it ideal 
for establishing intracellular [Cl-], as it can alter [Cl-]i without changing the resting 
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membrane potential of the cell.  While all the KCCs are activated by cell swelling, KCC2 
is unique in that it is constitutively active in isotonic conditions (Payne et al., 1996; 
Payne, 1997; Williams et al., 1999).  
There are several known pharmacologic stimulators and inhibitors of KCC2 
activity, although they are not specific for KCC2 in particular.  The alkylating agent N- 
ethylmaleimide (NEM) has been shown to activate 86Rb uptake by KCC2.  The loop 
diuretics furosemide and bumetanide are known inhibitors of this KCC2 activity, with 
KCC2 having a higher sensitivity to furosemide than bumetanide (inhibition constant (Ki) 
of ~25 µM and ~55 µM, respectively). Furthermore, compounds known to inhibit K-Cl 
transport in red blood cells likewise have been shown to inhibit KCC2.  The stilbene 
disulfonic acid DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid) and the alkanoic 
acid DIOA ([(dihydroindenyl)oxy]alkanoic acid) have been shown to inhibit 
approximately 80% of furosemide-sensitive flux at a concentration of 100 µM. (Payne, 
1997) 
KCC2 regulation is influenced by phosphorylation and dephosphorylation, 
although the exact mechanisms and pathways involved are not precisely understood 
(Figure 4).  PKC activation has been previously shown to decrease KCC2 surface 
expression and activity when expressed in oocytes (Bergeron et al., 2006). However, a 
recent study has shown that, in HEK293 cells and cultured neurons, protein kinase C 
phosphorylation of a serine residue in the carboxyl terminus increases KCC2 cell surface 
expression by decreasing the rate of transporter endocytosis (Munoz et al., 2007). 
NKCC1
Phosphatase
Kinase
Kinase
Phosphatase
Active
P
Inactive
Na+ K+ Cl- Cl-
NKCC1
KCC2
K+ Cl-
KCC2P
Figure 4. NKCC1 and KCC2 are regulated by
phosphorylation/dephosphorylation.
NKCC1 and KCC2 are regulated by opposing phosphorylation pathways. NKCC1
is activated by phosphorylation, whereas KCC2 is activated by dephosphorylation.
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Co-application of IGF-1 and c-src has been shown to rapidly activate KCC2, post-
translationally, in immature neurons, suggesting that protein tyrosine phosphorylation 
pathways are key to KCC2-mediated transport (Kelsch et al., 2001). 
Another interesting emerging story is the effect of SPAK (Ste20-related proline-
alanine-rich kinase) and WNK (With No Lysine/(K)) kinases on KCC2 function.  SPAK 
was first identified as an interactor with the N-terminus of KCC3.  Piechotta et al 
identified the SPAK binding motif on the cotransporter as [R/K]-F-x-[V/I] and 
subsequent analysis of the other CCCs identified two SPAK binding sites on 
NKCC1.(Piechotta et al., 2002) Yeast two-hybrid library screening with SPAK identified 
WNK4 and other proteins related to the stress-response pathway as potential interactors.  
This data, along with further characterization of SPAK binding and NKCC1 function, 
suggested a role of SPAK as not just a kinase, but as a scaffolding protein as well 
(Piechotta et al., 2003). The current working model of NKCC1 activation suggests WNK 
phosphorylates  SPAK, which in turn leads to SPAK translocation to the membrane for 
phosphorylation and activation of NKCC1 (Gagnon et al., 2006; Delpire and Gagnon, 
2008).    
 Yeast two-hybrid has demonstrated that the N-terminus of KCC2b, the original, 
and most prevalent KCC2 isoform, still interacts with the kinase even though it lacks a 
[R/K]-F-x-[V/I] motif (Gagnon et al., 2006). Additionally, strong evidence suggests that 
SPAK and WNK also have an effect on KCC2 activity.  KCC2 activity is significantly 
decreased by coexpression of SPAK and WNK4 in both isosmotic and hyposmotic 
conditions.  Interestingly, in isosmotic conditions, a switch to kinase-dead SPAK causes a 
significant increase in flux compared to KCC2 alone.  However, in hyposmotic 
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conditions, a switch to inactive SPAK or omitting SPAK expression altogether leads to a 
decrease in KCC2 flux compared to KCC2 alone (Gagnon et al., 2006). Considering the 
opposing roles KCC2 and NKCC1 have in regulating intracellular chloride, it seems 
fitting that while SPAK and WNK4 contribute to NKCC1 activation, these same kinases 
can in turn cause KCC2 deactivation.  
The newly identified isoform of KCC2, KCC2a, contains a putative SPAK 
binding motif in the 40 amino acids unique to this isoform of KCC2 (Uvarov et al., 
2007).  Experiments testing the effects of SPAK on KCC2a are yet to be performed, but it 
will be interesting to learn how SPAK affects this KCC2 isoform. 
 
BDNF and KCC2 
The neurotrophin BDNF has been shown to modulate KCC2, but with seemingly 
paradoxical effects. BDNF overexpressing mice exhibit increased KCC2 expression 
(Aguado et al., 2003). On the other hand, exogenous application of BDNF causes a dose-
dependent and time-dependent (length of exposure) downregulation of KCC2 mRNA and 
protein levels (Rivera et al., 2002). 
Rivera et al. have also studied stimulation of GABAergic inputs to CA1 neurons, 
and have demonstrated that rat hippocampal slices bathed in BDNF were depolarizing, as 
opposed to hyperpolarizing responses seen in control conditions (Rivera et al., 2002; 
Rivera et al., 2005). In a follow-up study, the same group further elucidates this 
mechanism of BDNF-mediated alterations in KCC2 expression and GABAergic 
response.  When hippocampal slices were incubated in Mg2+- free solution to generate 
continuous interictal activity, there was a decrease in KCC2 mRNA and KCC2 protein.  
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Slices in Mg2+- free solution containing NBQX (1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-
benzo[f]quinoxaline-7-sulfonamide) and AP-V (DL-2-Amino-5-phosphonopentanoic 
acid) to block seizure-like interictal activity do not show the same KCC2 decreases, 
demonstrating that it is the activity, rather than Mg2+ withdrawal alone, that causes this 
downregulation of KCC2, primarily in the CA1 region.  Using biotinylation experiments, 
the authors also show that the turnover and degradation of cell-surface KCC2 is increased 
in Mg2+- free solution, due to interictal activity.  Fitting with their previous data, when 
they measure IPSPs in the CA1 region of hippocampal slices, Mg2+-free solution and 
consequent activity causes a depolarizing shift in the IPSP reversal potential.  They also 
show that the BDNF’s effect on KCC2 occurs via the tyrosine kinase receptor B (TrkB). 
Transgenic mice with mutant TrkB lacking either the Phospholipase C or Shc docking 
sites do not undergo the same amount of KCC2 downregulation compared to control 
mice (Rivera et al., 2004; Rivera et al., 2005). 
 
Protein interactions with KCC2 
At the initiation of this project, there were no known protein-protein interactions 
with KCC2.  Since then, two novel interactions have been reported.  The first, reported in 
2004, is the interaction between KCC2 and brain creatine kinase (CKB) (Inoue et al., 
2004).  The functional significance of this interaction was explored in a follow-up 
functional study using HEK293 cells and cultured cortical neurons. Heterologous 
expression of dominant negative CKB, glycine receptors, and KCC2 in HEK cells causes 
a depolarizing shift in the reversal potential of glycine.   In neurons, application of the 
creatine kinase inhibitor, 2,4-dinitrofluorobenzene (DNFB), caused a depolarizing shift in 
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the GABA reversal potential (Inoue et al., 2006). Thus, it is suggested that one native role 
of CKB is to activate KCC2 activity. 
Second, the cytoskeleton-associated binding protein 4.1N has been found to bind 
to KCC2, as well.  Neurons cultured from KCC2 knockout mice have abnormal dendritic 
spine morphology and fewer functional dendritic synapses as compared to controls.  In 
KCC2 -/- neurons, this phenotype is rescued by transfecting KCC2 mutant lacking the 
carboxyl terminus.  Conversely, transfection of KCC2-CT alone into wild type neurons 
causes long dendritic spine protrusions similar to those seen in KCC2-/- mice.  This led 
Li et al to examine KCC2-CT binding partners by immunoprecipitation and immune 
blotting for several proteins highly enriched in dendritic spines, from which they 
identified 4.1N as a KCC2 binding partner.    The authors suggest that KCC2 in 
association with 4.1N may act as a synchronizing factor for synaptogenesis, perhaps by 
governing the neuron’s response to glutamatergic and GABAergic signaling, and thus 
coordinating formation of inhibitory and excitatory synapses (Li et al., 2007). 
 
Physiological significance of KCC2 function 
KCC2 and GABAergic signaling 
Because of its unique kinetic properties in isotonic conditions, KCC2 is proposed 
to serve as a buffer for external K+ concentration in the direct vicinity of neurons, and to 
maintain intracellular Cl- concentrations necessary for inhibitory GABA and glycine 
responses (Payne, 1997; Lu et al., 1999; Rivera et al., 1999; DeFazio et al., 2000; 
Delpire, 2000; Vardi et al., 2000). 
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The role of KCC2 in GABAergic neuronal communication is one of the more 
well-studied aspects of KCC proteins.  The GABA response in immature brain is 
excitatory due to large depolarizing responses, whereas in the mature brain it is 
inhibitory. At birth, KCC2 expression is minimal, and increases markedly during 
postnatal development. This upregulation coincides with the switch of GABA and 
glycine responses from depolarizing to hyperpolarizing (Lu et al., 1999; Rivera et al., 
1999). Viewed in light of KCC2 localization in GABAergic neurons and colocalization 
with the β2/β3-subunits of the GABAA receptor (Payne et al., 1996; Williams et al., 
1999), such data support KCC2 as the neuronal Cl- extruder which establishes the low 
[Cl-]i and modulates GABA-stimulated responses (Figure 5). 
Several studies have provided evidence for the role of KCC2 in modulating 
intracellular Cl- (Kakazu et al., 1999; Rivera et al., 1999; DeFazio et al., 2000; Kakazu et 
al., 2000; Vardi et al., 2000; Nabekura et al., 2002; Ueno et al., 2002; Zhu et al., 2005). 
For instance, in bipolar retinal neurons GABAA receptors are distributed equally among 
dendrites. However, the localized dendritic expression of KCC2 allows GABA to 
produce different effects on opposite poles of the same neuron (Vardi et al., 2000). 
Development in the retinotectal circuit is dependent on the shift in intracellular chloride 
([Cl-]i) and targeted KCC2 expression in these developing neurons by electroporation is 
sufficient to prematurely shift [Cl-]i and interfere with GABAergic signaling, and also 
with synaptic development of the retinotectal circuit (Akerman and Cline, 2006).  
In some situations, GABA can act as an excitatory neurotransmitter even in 
mature neurons with normal adult levels of [Cl-]i.  Coincident stimulation of neurons at 
dendrites and soma can create a shunting effect, resulting in a net depolarization due to 
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Figure 5. Intracellular Cl is altered by CCC expression.
-
Top panel: Model of an immature neuron illustrating higher expression of the
Na-K-2Cl cotransporter than KCC2 cotransporter, thus resulting in a high
intracellular Cl concentration (dark shading). Release of GABA then results in
Cl exit through the ionotropic GABA receptor, membrane depolarization, and
excitatory neurotransmission. Bottom panel: In a mature neuron, expression of the
KCC2 K-Cl cotransporter is greater than NKCC1, resulting in a lower
intracellular Cl concentration (light shading). Thus, release of GABA results in
Cl movement into the cell, membrane hyperpolarization, and inhibition.
-
-
-
-
A
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 bicarbonate transport by the GABAA receptor (Gulledge and Stuart, 2003).  However, 
KCC2 subcellular distribution in cortical neurons can similarly affect the membrane 
potential response to GABA in mature cells. For instance, axon initial segments of 
pyramidal neurons are almost exclusively innervated by GABAergic axo-axonal cells.  
Absence of KCC2 in this localized region causes GABA to be depolarizing, even in 
mature neurons (Szabadics et al., 2006) 
Cortical neurons from transgenic KCC2 knockout mice having 3 to 5% of normal 
KCC2 expression, unlike their wild type controls, show no developmental decreases in 
[Cl-]i. Moreover, when challenged with membrane depolarization, neurons lacking KCC2 
cannot maintain existing intracellular chloride levels, or regulate chloride when 
challenged with chloride loading (Zhu et al., 2005). Expression of KCC2 is upregulated 
by increased spontaneous GABAergic activity and downregulated following blockade of 
GABAA receptors, demonstrating that GABA-mediated depolarization itself can then 
increase KCC2 expression and promote the maturation of the inhibitory response 
(Ganguly et al., 2001). 
 
Animal models of KCC2 dysfunction 
Studies of animal models with disruptions in KCC2 also indicate that this 
cotransporter plays an important role in neuronal communication.  A full knockout of 
KCC2 in mice resulted in death shortly after birth, due to respiratory failure and 
consequent hypoxia (Hubner et al., 2001; Stein et al., 2004). 
Mice with a targeted deletion of the exon 1b of KCC2 resulted in a 95% 
knockdown of KCC2 expression.  Homozygous mice have tonic-clonic type seizures, 
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consisting of generalized limb stiffness, and die early, approximately two weeks after 
birth. These seizures could be induced by handling of the mice, as well.  Homozygotes 
also had a decrease of KCC2 in parvalbumin-expressing interneurons in the brain, which 
follows previous reports of a loss of these neurons after seizures.  
Common anti-convulsant pharmacologic agents were tested in these mice, as well. 
The GABAA agonist diazepam temporarily alleviated seizure activity, but was ineffective 
for long-term use or for prevention of future seizures. Phenytoin, another commonly used 
anti-convulsant drug, had a more lasting effect on alleviating seizures than diazepam, and 
also curbed the growth deficiencies seen in these KCC2 lacking mice.  However, 
phenytoin efficacy decreased after approximately 12 days after birth.  Seizures were 
exaggerated by administration of picrotoxin, a blocker of GABAA receptors. 
Heterozygote mice did not have an obvious phenotype but were more susceptible to 
seizures due to administration of the GABAA blocker pentylenetetrazole (Woo et al., 
2002). 
A Drosophila homologue to the mammalian KCC2 has also been identified 
through a screen for seizure-enhancing mutations. Named kazachoc (kcc), after the Slavic 
dance in which dancers squat and stiffly kick out alternating legs, this gene reduces 
seizure threshold in flies, functioning via GABAA mediated pathways (Hekmat-Scafe et 
al., 2006). 
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KCC2 and ischemia 
Following stroke, brain damages include an overload of potassium due to K+ 
release, and seizure susceptibility.  As a neuronal transporter of both potassium and 
chloride, KCC2 is well situated to be involved in post-ischemic brain damage, and 
several studies support this notion, as well.  In rat models, global ischemia causes 
seizures in response to intense auditory stimulation.  The loop diuretics furosemide and 
bumetanide, inhibitors of KCC2, temporarily blocked seizure susceptibility, whereas the 
osmotic diuretic mannitol did not.  Furosemide and bumetanide, however, does not 
prevent seizures induced by the GABAA receptor antagonist bicuculline.  Also, it is noted 
that these chemical agents, which are not specific to KCC2, would not be clinically useful 
due to their potent diuretic effects (Reid et al., 2000). Another study has shown that 
ischemia raises levels of KCC2 mRNA which more strongly links post-ischemia seizure-
susceptibility to alteration of KCC2 expression and/or function (Reid et al., 2001). 
 
KCC2 and human disease 
Changes in KCC2 levels in various forms of epileptic diseases suggest that the 
cotransporter plays a role in these disease states.  Hippocampal sclerosis (cell loss) is 
often seen in patients of temporal lobe epilepsy.  Normal patient hippocampi exhibit a 
high level of NKCC1 and KCC2  colocalization throughout the hippocampus, but in 
epileptic patients, NKCC1 and KCC2 are colocalized in the non-sclerotic regions (CA4 
and subiculum) but 20% less so in the sclerotic CA1 region and the subiculum-CA1 
border areas (Munoz et al., 2007). 
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Patients with malformations in cortical development (e.g., focal cortical dysplasia, 
ganglioglioma, hemimegalencephaly) have altered KCC2 distribution, with low KCC2 
immunoreactivity in the neuropil, but high levels of staining localized to cell somas in 
dysplastic cells (Aronica et al., 2007). 
Temporal lobe epilepsy patients show upregulated NKCC1 and slightly 
downregulated KCC2 in the hippocampal regions, as compared to neocortex. Injecting 
oocytes with membranes preps made from hippocampal tissues from these patients 
causes oocytes to depolarize in response to GABA. This can be blocked by adding 
bumetanide, an inhibitor of NKCC1, further suggesting that the EGABA shift seen in 
oocytes is due to the altered NKCC1 expression in the TLE patient brain tissues (Palma 
et al., 2006). 
Searching the NIH-NCBI database for reported human single nucleotide 
polymorphisms, there are six SNPs in human KCC2 which are nonsynonymous (resulting 
in an amino acid change) and fall within coding regions.  None of these SNPs have had 
any further testing or examination, but this is indeed an avenue worth exploring, either 
studying the functional effect of these mutations in experimental laboratory models, or in 
human population studies which might link these mutations to diseases such as epilepsy. 
 
KCC2 and pain 
KCC2 has been implicated in playing a role in pain perception. Injury in rat facial 
neurons and dorsal motor neurons of the vagus nerve imparted by transection of axons 
causes a downregulation in dendritic KCC2 expression, subsequent increase in [Cl-]i, and 
a depolarizing shift in the GABA response (Nabekura et al., 2002; Toyoda et al., 2003).  
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Sciatic nerve constriction in rats causes an ipsilateral decrease in KCC2 expression and 
increased EGABA in spinal lamina I neurons.  Nociceptive threshold was also decreased by 
antisense KCC2 mRNA administration into the spinal cord (Coull et al., 2003). Injury 
evoked by formalin injection into the rat hindpaw also causes a downregulation of KCC2 
in spinal cord neurons, coincident with increases in flinching, a behavior indicative of 
heightened sensitivity to pain (Nomura et al., 2006). Further study of peripheral nerve 
injury, using loose ligation of rat sciatic nerve, demonstrates that KCC2 protein decreases 
are accompanied by increases in BDNF, and early behavioral signs of pain are attenuated 
by pretreatment with tyrosine kinase blocking drug or BDNF-sequestering scavenger 
proteins.  The KCC2 protein changes and TrkB-mediated effects are, however, immediate 
and transient.  One week after injury, KCC2 protein levels match controls and no 
chemical or scavenger protein disruption of the BDNF pathway attenuates pain behavior 
(Miletic and Miletic, 2007).  Two mechanisms thought to be involved in KCC2’s 
contribution to neuropathic pain include disinhibition of non-nociceptive fibers synapsing 
on spinal neurons, or perhaps the conversion of normally inhibitory low-action potential 
threshold GABA pathways to excitatory (Price et al., 2005). 
 
Summary 
KCC2, a member of the cation-chloride cotransporter (CCC) family, is a critical 
modulator of neuronal function, chiefly through its involvement in chloride regulation 
and GABAergic signaling.  As an electroneutral cotransporter of potassium and chloride, 
it is an ideal establisher of the intracellular chloride concentration in neurons.  Powered 
by the potassium gradient set by the Na+-K+ pump, KCC2 extrudes chloride from 
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neurons, resulting in a low internal chloride concentration without changing the reversal 
potential of the cell.  This in turn causes the neurotransmitter GABA to have a 
hyperpolarizing effect, as the GABAA receptor is an ionotropic receptor primarily 
selective for chloride.   
A full knockout of KCC2 expression in mice leads to death shortly after birth, 
while a knockdown of KCC2 expression results in a seizure phenotype, and death 
approximately two weeks after birth.  A genetic screen for seizure-enhancing mutations 
in Drosophila demonstrates that KCC2 disruption contributes to seizure susceptibility, as 
well.  These animal models demonstrate that KCC2 is essential to preventing 
overexcitability in the nervous system.   
Ischemic injury, pain states, and seizure disorders have been linked to KCC2 
function and expression.  Post-mortem studies of epilepsy patients show that KCC2 
levels are altered in patients.  Given the knowledge that KCC2 is important to inhibition 
in the nervous system, it seems likely that this KCC2 downregulation is the origin of 
epileptiform activity.  However, electrophysiological experiments in rat brain slices seem 
to indicate that interictal activity causes a downregulation of KCC2 expression.  It is 
possible that KCC2 can be involved with the origin as well as response and/or 
propagation of epileptiform activity, but more studies will need to be done to make these 
distinctions. 
Given the importance of KCC2, relatively little is known about its regulation.  Net 
dephosphorylation leads to stimulation of cotransporter activity, yet specific targets and 
kinases are yet to be definitively established.  Stress-signaling pathways may affect 
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KCC2 via the Ste20-related kinase SPAK.  BDNF and TrkB signaling likewise play a 
role in KCC2 activation. 
Understanding protein interactions of membrane-bound transporters is a key 
aspect to understanding how these transporters are regulated.  At the initiation of this 
project, no known interactors with KCC2 had been identified.  Thus, this thesis project 
aims to determine and characterize novel protein interactions with KCC2, as described by 
the following hypotheses and specific aims. 
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Hypothesis and specific aims: 
Very little is known about the regulation of KCC2, especially considering many 
convincing studies demonstrating its important role in neuronal communication. 
Regulation of membrane transporters often requires interaction with other proteins, some 
involved in trafficking, and others in posttranslational modifications.  This has led me to 
explore the first hypothesis: 
 Hypothesis I.: KCC2 interacts with other proteins on its carboxyl terminus, and 
these potential interactors affect KCC2 function and/or expression.  
¾ Specific Aim 1:  Identify novel interactors with the KCC2 carboxyl terminus 
 
As described in Chapter I, a yeast two-hybrid screen identified PAM/Phr1 as a 
potential interactor with the KCC2-CT.  This potential interactor is interesting for several 
reasons, as described in Chapter II.  Since PAM is a large protein, I used only the portion 
of the protein identified in the screen in the following experiments, from now on called 
RCC1/PAM. This leads me to my second hypothesis: 
Hypothesis II.: RCC1/PAM binds to KCC2 and affects its function. 
¾ Specific Aim 1:Investigate effect of RCC1/PAM on KCC2 activity and expression 
in HEK293 cells 
¾ Specific Aim 2: Characterize PAM binding to create a targeted point mutation 
disrupting interaction between PAM and the KCC2-CT 
¾ Specific Aim 3: Compare mutant KCC2 expression and activity to wild type KCC2 
in the presence of RCC1/PAM 
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CHAPTER II 
 
IDENTIFICATION OF PROTEIN INTERACTORS OF THE KCC2 CARBOXYL 
TERMINUS USING YEAST TWO-HYBRID 
 
Introduction 
There are many paths to begin the journey to understanding the physiological role 
of a particular protein.  These paths take many forms, from transgenic methods, such as 
deleting a gene from a model organism, to genomic meta-analyses, such as studying 
SNPs in humans afflicted by a particular disease.  Screening a protein for potential 
binding partners also can be a particularly rewarding and fruitful beginning, as it can 
uncover obscure or unexpected associations between two proteins, thus potentially 
linking together two or more signaling pathways, and contributing to a greater 
understanding of both proteins.   
The yeast two-hybrid system is a powerful method of screening for novel protein-
protein interactions.  Developed in the late 1980s, it has been utilized by many 
researchers for identification of novel protein interactions.  Stanley Fields, developer of 
the yeast two-hybrid system, attributes yeast two-hybrid’s power and subsequent 
popularity to its elemental implications,  stating, “The two-hybrid system addresses one 
of life’s fundamental questions: How does one find a meaningful partner?”   
 The yeast two-hybrid system can be used to test interaction between two known 
proteins, or to use a protein to screen a library for novel interactors.  In both cases, 
transcription factor assembly and reporter gene expression act as a read-out of protein-
protein interaction.  In a library screen to identify novel interactors, the protein of 
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interest, the “bait,” is fused to one half of a yeast transcription factor, the activating 
domain or the binding domain.  The “fish” proteins are made from a cDNA library and 
fused to the remaining half of the transcription factor.  If the bait and fish proteins 
interact, the transcription factor domains come in close proximity, thus allowing binding 
to specific promoter region, and activation of reporter genes downstream of this 
promoter, engineered into the yeast strain’s genome (Figure 6).  Such reporter genes 
include beta-galactosidase or various amino acid auxotrophy genes.  Conversely, proteins 
which do not interact do not bring the transcription factor activating and binding domains 
together, and thus no reporter gene transcription can occur.  
Since its inception, the yeast two-hybrid system has been further modified to 
enhance its capabilities. For example, a mammalian two-hybrid system utilizes 
mammalian cells, as opposed to yeast, which is ideal if factors native to mammalian cell 
nuclei need to be present for binding to occur (Feng and Derynck, 2001).  Three-hybrid 
systems can be used to identify interactions which necessitate three binding partners, 
such as two proteins and an interaction-regulating factor (e.g., kinase, phosphatase, 
methylase) (Sandrock et al., 2001).  The yeast split-ubiquitin system can be used to study 
protein interaction in the membrane or cytosol (Thaminy et al., 2004; Mockli et al., 
2007).  However, the core concept of the original yeast two-hybrid system remains in 
these variations. 
Our lab has previously had success using yeast two-hybrid to identify interactions 
in library screens, such as with KCC3 and SPAK (Piechotta et al., 2002) and SPAK, 
WNK, and apoptosis associated tyrosine kinase (AATYK) (Piechotta et al., 2003)  
BD
KCC2-CT
Uracil
GAL4 BD plasmid (pGBDUc2)
Promoter Reporter Gene
GAL4 Activation Domain (AD)
GAL4 Binding Domain (BD)
KCC2-CT
Mouse brain proteins
Transcription
Activator
Complex
Histidine
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Mouse brain cDNA library
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Figure 6. Yeast two-hybrid as a test of protein interaction.
The carboxyl terminus of KCC2 (KCC2-CT) was subcloned into the yeast two-
hybrid vector pGBDUC2 which contains a Gal 4 binding domain. cDNA clones
from a mouse brain library were fused to the Gal 4 activating domain in pACT2.
Protein interaction between KCC2-CT and the protein, or partial protein,
produced from the cDNA library clone will likewise bring together Gal 4
activating and binding domains, forming a transcription activator complex which
can then activate transcription of yeast reporter genes.
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(Delpire and Gagnon, 2007), as well as in testing specific proteins with small-scale yeast 
two-hybrid transformations.  Thus, based on past successes of the laboratory, the same 
yeast two-hybrid reagents and protocols were utilized for identifying novel interactors 
with KCC2.   
 The KCC2 carboxyl-terminal tail (KCC2-CT) was chosen as the “bait” protein 
for this screen because it contains several interesting characteristics which make it a 
likely interface for transporter regulation (Figure 7).  The intracellular carboxyl tail of 
KCC2 is very large, making up approximately 45% of the entire protein. The KCC2-CT 
contains several putative protein kinase C phosphorylation sites, one which has been 
recently shown to affect cotransporter stability at the cell surface (Payne et al., 1996; 
Munoz et al., 2007).  The KCC2 carboxyl tail contains a unique 34 amino acid sequence 
of the KCC2 C’-terminus, which is not conserved in other KCC isoforms.  Heterologous 
expression of KCC2, KCC1, and KCC1/KCC2-CT chimeras suggest this sequence is 
responsible for its constitutive activity in isotonic conditions (Mercado et al., 2006). 
Additional KCC2 chimera studies demonstrate that proximal, central, and distal regions 
of the C terminus play a role in ion transport aside from PKC-mediated effects (Bergeron 
et al., 2006). In addition, a tyrosine residue on the C’ tail located at position 1087 is 
necessary for KCC2 function, however, not via phosphorylation (Strange et al., 2000). 
Taken together, these facts suggest that the carboxyl terminus is an important contributor 
to KCC2 function and a likely site for multiple protein-protein interactions.  This has led 
me to explore the identification of novel KCC2 interactors, specifically focusing on the 
carboxyl terminus.   
Figure 7. Domains and features of the KCC2 carboxyl terminus.  
The KCC2 carboxyl terminus sequence, shown here, contains many regions of 
interest. A KCC2-specific sequence in double underscored and highlighted in 
yellow.  Two PEST sequences are outlined by a dotted box.  Asterisk indicates a 
serine residue verified as a PKC phosporylation site. The pound sign denotes a 
tyrosine residue critical for function, but not via phosphorylation.  The dashed 
underline indicates a predicted GGDEF domain, which is a domain homolgous 
to adenylyl cyclase.
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Methods 
Amplification of mouse brain cDNA library 
The mouse brain cDNA library in the pACT2 vector in E. coli was obtained from 
Clontech (Mountain View, CA). The library was amplified such that the total number of 
colony forming units (cfu) plated would be greater or equal to three times the target 
number of cDNA library clones to be screened. The Clontech titer of their library equals 
108 cfu/ml, and the target number of clones to be screened was 3.5 x 106.  Therefore, 120 
µl of bacteria was resuspended in 50 mL LB medium, and 200 µl of this diluted library 
was plated on 250 150-mm LB/agar plates (250 plates x ~40,000 cfu/plate = 11 x 106 
cfu). Bacteria plates were grown for 2 days at 30°C, then scraped and pelleted for DNA 
isolation using the Qiagen MegaPrep Kit 2500. The titer results indicated 20,000 
cfu/plate. 
 
Generation of bait/KCC2 carboxyl terminus  
To perform a yeast two-hybrid screen, a protein fragment or polypeptide needs to 
be inserted into a yeast vector, such that it is in frame with the GAL4 binding domain. To 
do so, a sense oligonucleotide PCR primer was designed with a restriction site allowing 
ligation in the proper frame and an anti-sense oligonucleotide PCR primer is designed 
with a stop codon followed by a restriction site. Thus, a portion of the carboxyl terminus 
of the rat KCC2 (KCC2-CT) was amplified by PCR using an existing rat KCC2 cDNA 
clone and primers 8S and 9A.  PCR fragment was ligated into the pGEM vector, and 
pGEM clones were checked with restriction enzyme mapping before sequencing with 
ABI Prism Big Dye Terminator (Applied Biosystems, Foster City, CA) using the 8S, 9A, 
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T7 and SP6 primers (see Table 1). The PCR fragment was removed by digestion with 
BamHI and SalI DNA restriction enzymes, and then ligated into the pGBDUC2 vector 
(xBamHI, xSalI) in frame with the Gal4 binding domain.  All sequences in pGBDUC2 
were checked using the GB1 and GB2 primers. 
 
Table 1: Primers used for yeast two-hybrid DNA constructs 
Primer Name Primer Sequence  (5’ to 3’) 
8S CGGAATTCCGGGGGGCAGAGAAGGAGTGGGG 
9A GAAGATCTTCAGGAGTAGATGGTGATGACCTC 
T7 AATACGACTCACTATAG 
SP6 ATTTAGGTGACACTATAG 
GB1 ATAAGTGCGACATCATCATCG 
GB2 TTCAGTATCTACGATTCATAG 
 
 
Yeast culturing 
The yeast strain PJ69-4A was used for all yeast two-hybrid work (Pramfalk et al., 
2004), as this is a widely used two-hybrid strain with several reporter genes engineered 
into its genome.  Additionally, protocols for this particular strain are well-established in 
our laboratory. All yeast cultures were grown at 30°C, and stored short-term at 4°C. 
Yeast cells, untransformed with any plasmids, were grown on YPDA plates which 
contained all essential amino acids for growth. Yeast transformed with pACT2 vectors 
were maintained on -Leucine plates, and those transformed with pGBDUC2 vectors were 
maintained on -Uracil plates. For long term storage, yeast cells were resuspended in 25% 
glycerol and stored at -80°C.  
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Library screen   
Sequential yeast transformations were performed to introduce the bait and fish 
plasmids into the yeast.  First, the KCC2-CT- pGBDUC2 plasmid was transformed into 
PJ69-4A yeast cells (Pramfalk et al., 2004). This transformed yeast was then used in 
another library-scale transformation in order to screen the amplified mouse brain cDNA 
library in pACT2 vector. Transformed yeast from the screen were subject to nutritional 
selection, first by plating the yeast cells on 150mm -Uracil/-Leucine/-Adenine plates, 
then by two rounds of picking and restreaking surviving clones onto -Uracil/-Leucine/-
Histidine + 2 mM 3-amino-1,2,4-triazole (3-AT)  plates.  All plates were incubated at 
30°C, and in plastic bags to avoid drying. Surviving colonies were picked 4 and 9 days 
after transformation or restreaking. 
 
Library titer 
A library titer was performed in order to estimate how many yeast colony forming 
units (cfu) were successfully transformed with both the bait/pGBDUC2 and fish/pACT2 
plasmids. The library transformation suspension was serially diluted in 1:10, 1:100 and 
1:1000 ratios, and 100 µl of each dilution spread on a -Uracil, -Leucine drop-out media 
plate.  The transformation efficiency was calculated by counting cfus growing on the -
Uracil, -Leucine plates containing 30-300 cfus. 
cfu x total suspension vol. (µl)  
=  cfu/µg DNA [Vol. plated (µl)] x [dilution factor] x [amount DNA used(µg)]
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Liquid LacZ Assays  
As an additional level of stringency to use in conjunction with Histidine and 
Adenine auxotrophy, yeast clones were assayed for LacZ/beta-galactosidase activity.  For 
this assay, several colonies from one clone were picked to grow overnight in 14 mL         
-Uracil, -Leucine, -Histidine liquid media at 30°C. 1 ml of the overnight culture (at 
stationary phase, ODλ600>1.5) was transferred into 4 ml of YPDA medium, and 
incubated at 30°C at 250 rpm for approximately 3 hrs, until ODλ600 = 0.5 ± 0.1. 
Following two spin/wash cycles with 1x PBS, pelleted yeast cells were lysed with lysis 
buffer and incubated at 37°C for 3 hrs with ONPG assay buffer (120 mM Na2HPO4 , 80 
mM NaH2PO4, 2 mM MgCl2, 100 mM β-mercaptoethanol, 1.33 mg/ml ONPG (Sigma)).  
The reaction was stopped by addition of Na2CO3, centrifuged, then read in a 
spectrophotometer at λ420nm. 
 
Clone identification  
Yeast clones with the highest β-galactosidase expression were lysed with 10µl 5x 
Reporter Lysis Buffer (Promega, Madison, WI) for 10 minutes at 37°C then subjected to 
PCR using the YST1 and YST2 primers and the ExpandLong Template PCR kit (Roche, 
Indianapolis, IN).  
Amplified PCR fragments were then sequenced with ABI Prism Big Dye 
Terminator (Applied Biosystems, Foster City, CA) using the YSEQ primer. 
In situations where direct PCR of lysed yeast cells did not yield readable 
sequences, clone plasmids were rescued from yeast cells by incubation in 10µl lyticase, 
heat shock at 37°C for 1 hour, incubation with 10µl 20% SDS, and one freeze-thaw 
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cycle. DNA was then extracted with phenol:chloroform:isoamyl and ethanol 
precipitation, then transformed into competent E. coli cells.  E. coli clones were picked 
and grown on duplicate nitrocellulose filter paper grids, then subject to Southern blotting 
using 32P-labelled cDNA probes made from the pACT2 plasmid.  Positive E. coli clones 
containing pACT2 were picked from the duplicate plate, then grown and miniprepped for 
DNA, and then sequenced with the YSEQ and GB2 primers (see Table 2).  The 
sequences which were in frame with the Gal binding domain were identified using 
BLAST on the NIH-NCBI website.  
 
Table 2: Primers for Clone Identification 
Primer Name Primer Sequence  (5’ to 3’) 
YST1 GAAGTGAACTTGCGGGGTTTTTCAGTATCTACG 
YST2 CTATTCGATGATGAAGATACCCCACCAAAC 
YSEQ CCATACGATGTTCCAGATTACGCTAGC 
GB2 TTCAGTATCTACGATTCATAG 
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Results 
Library titer plates made of -Uracil, -Leucine media were used to control for 
transformation efficiency, as well as to calculate the number of mouse brain library 
clones screened.  The library titer plates grew 91 clones (1:1000 dilution) and 968 clones 
(1:100 dilution) and the entire library screen transformation was plated on 65 plates.  
Therefore an estimated range of 5,915,000 to 6,292,000 total library clones were 
screened.  [65*(91x103 + 968x102)] 
An initial pool of approximately 900 clones was retrieved from the initial 
selection by plating on -Uracil/-Leucine/-Adenine plates.  Following nutritional selection 
by picking and restreaking onto -Uracil/-Leucine/-Histidine +3-AT plates, twice in 
succession, the pool of clones was narrowed to 50 candidates.  These surviving clones 
were then assayed using a liquid LacZ colorimetric assay to assess the level of expression 
of the beta-galactosidase reporter gene.  After selecting the clones with the highest LacZ 
values, we arrived at a final pool of candidate proteins.  These were sequenced and 
identified using BLAST searches (NIH-NCBI).  Clones were excluded if they encoded 
for known false positives in the yeast two-hybrid system (e.g., elongation factors, heat 
shock proteins), as well as if they were not in the same translational frame as the Gal4 
Activating domain, or if they encoded 3’UTR regions. Figure 8 shows the top list of 
candidates identified which meet this criteria (upper panel) as ranked by the galactosidase 
activity determined from the liquid LacZ assays (lower panel). 
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Rank Clone # [Gal] Protein 
1 7 7.633 Protein Associated with Myc 
2 106 6.616 Protein Associated with Myc 
3 469 4.132 Protein Associated With Myc 
4 3 1.954 Ran Binding Protein 9 
5 44 1.491 KIAA1140/Tetratricopeptide repeat protein 7A 
6 430 0.900 KIAA1140/Tetratricopeptide repeat protein 7A 
7 446 0.794 KIAA1140/Tetratricopeptide repeat protein 7A 
8 442 0.656 Brain Creatine Kinase 
9 102 0.400 KIAA1140/Tetratricopeptide repeat protein 7A 
10 26 0.340 Ran Binding Protein 9 
11 424 0.277 Brain Creatine Kinase 
12 341 0.270 Brain Creatine Kinase 
 
LacZ reporter gene activity of top scoring Y2H clones 
 
 
 
Figure 8. Candidates from yeast two-hybrid screen and LacZ assay data. 
Candidates from the yeast two-hybrid screen went through several rounds of selection, 
included plating/restreaking on media lacking Adenine or Histidine.  Surviving clones 
were the tested further in liquid LacZ assays to measure β-galactosidase activity, as 
well.  After sequencing high-activity clones to eliminate common false positives (e.g. 
elongation factors), proteins that were out of frame, and cDNAs from non-coding 
regions, a final list of candidates was created (upper panel) and ranked based on values 
obtained in LacZ assays (bottom panel). 
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Discussion 
Our library titer demonstrated that approximately 6 x 106 library clones were 
screened. This is a good number, as it is recommended that yeast two-hybrid screens of 
mammalian cDNA libraries should cover a minimum of 5 x 106 clones in order to have 
full coverage and saturation of representative cDNAs (Van Criekinge and Beyaert, 1999). 
 
“The greatest hits” 
 The top scoring candidates in this library screen included several very interesting 
candidates (Figure 8).  Of these, the highest LacZ activity came from a portion of Protein 
Associated with Myc, or PAM.  This protein is particularly intriguing due to the 
phenotypes of PAM homologue mutants in the fly and worm, as further discussed in 
detail in the next chapter.   
Another protein which appeared several times in our screen was the putative 
protein KIAA1140, or tetratricopeptide repeat domain protein 7A (TTC7). This protein 
was identified during a sequencing and protein prediction screen of large proteins 
expressed in the brain (Hirosawa et al., 1999). Tetratricopeptide repeat (or, TPR) domain-
containing proteins are characterized by a degenerate 34 amino acid consensus sequence 
forming a helical secondary structure, and proteins with this domain are involved in a 
variety of cell processes, from mitosis to protein scaffolding (Lamb et al., 1995; Blatch 
and Lassle, 1999). More studies on TTC7 were reported in 2005, in a study attempting to 
identify genes involved in iron homeostasis.  TTC7 was found to be mutated in two 
mouse mutant strains, one with an anemic phenotype, and the other with a flaky skin 
phenotype. Speculation about TTC7’s role include that it may be a candidate gene for 
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psoriasis, and may bind to iron transporters, however its exact function is not known 
(Helms et al., 2005; White et al., 2005). 
Another protein which came up several times in this screen is brain creatine 
kinase, or CKB.  Creatine kinase activity has been generally characterized in skeletal 
muscle cells.  It participates in intracellular energy storage and synthesis by 
phosphorylating creatine, consuming adenosine triphosphate (ATP) and producing 
adenosine diphosphate (ADP) in the process.  Brain creatine kinase likewise is a 
phosphoprotein which associates with mitochondria and participates in the energy cycle 
and ADP/ATP conversion and localization (Booth and Clark, 1978; Mahadevan et al., 
1984). Increase of plasma CKB levels in humans is suggestive of brain injury, and CKB 
rate constants increase before and during induced seizure activity in adult rats (Somer et 
al., 1975; Holtzman et al., 1997; Haskins et al., 2005). CKB changes have also been 
recently linked to bipolar disorder, amphetamine use, and Alzheimer’s disease, although 
it is not clear if changes in CKB activity are indicative of or resulting from progression of 
these conditions. (Castegna et al., 2002; Streck et al., 2008) 
Brain creatine kinase expression is highest in the brain, specifically in glial cells.  
However, its expression is not confined to the brain, but widespread through several 
tissue and cell types.  It is hypothesized that CKB acts as a rapidly reactive participant in 
energy synthesis, which is recruited into action for energy demanding processes, such as 
cell growth and development (Kuzhikandathil and Molloy, 1994; Willis et al., 1999). 
There have been several links between CKB and cancer, as well. CKB expression is 
highly upregulated in many tumor cell lines and CKB has been shown to be repressed by 
p53.  CKB upregulation is present in 78% of colon tumors, suggesting its use as a 
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biomarker for cancerous tumors, such as in the case of colorectal cancer (Kaddurah-
Daouk et al., 1990; Zhao et al., 1994; Kuzhikandathil and Molloy, 1999; Balasubramani 
et al., 2006). 
 The same interaction I identified between KCC2 and brain creatine kinase was 
later confirmed by another group’s yeast two-hybrid screen using the KCC2-CT (Inoue et 
al., 2004). They further explored this interaction in a follow-up functional study of 
glycine-receptor expressing HEK293 cells and cultured cortical neurons. HEK cells 
cotransfected with KCC2 and dominant negative CKB show a depolarizing shift in the 
glycine reversal potential. In neurons, the application of a creatine kinase inhibitor, 2,4-
dinitrofluorobenzene (DNFB), caused a depolarizing shift in the GABA reversal potential 
(Inoue et al., 2006). Thus, it is suggested that one native role of CKB is to activate KCC2 
activity. 
 
Considerations of the yeast two-hybrid system 
Yeast two-hybrid is a useful method for identifying novel protein-protein 
interactions, and has been used with success by our laboratory, and many other 
laboratories, in the past. There are, however, some pitfalls and drawbacks worth noting.  
The size and region of the bait protein impacts the fruitfulness of the yeast two-hybrid 
screen. Bait and candidate proteins cannot contain any transmembrane domains, as these 
hydrophobic structures will cause transport into the nuclear membrane, thus preventing it 
from activating the yeast reporter genes. Initially, I had sought out to identify interactors 
with the KCC2-specific region of the KCC2 carboxyl terminus (rKCC2 residues 929 to 
969). I also used both this region, as well as a larger region encompassing the KCC2-
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specific region in library-scale yeast two-hybrid screen. However, these regions were 
possibly too small, as they did not result in many hits for these screens.  
Yeast two-hybrid screens are also known to result in many false positives. Some 
aspects of our screening protocol help in evading such false leads. We use two different 
auxotrophy reporter genes as selection markers for positives: Adenine and Histidine, 
driven by two different Gal promoters.  Thus, candidate proteins which may 
independently act as a transcription factor would have to be able to bind to both 
promoters in order to pass through to the next stage of clone selection. Additionally, we 
use liquid LacZ assays as yet another level of stringency in selecting positive candidate 
interactors.   
However, confirming positives outside of the yeast system is also necessary.  In 
the next chapter, I examine the candidate interactor PAM more closely, and use GST 
pull-down assay and coimmunoprecipitation assays for confirmation outside the yeast 
system. 
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CHAPTER III 
 
VALIDATION OF KCC2 AND RCC1/PAM INTERACTION 
 
Introduction 
Portion of PAM identified 
The carboxyl-terminal tail of rat KCC2 (KCC2-CT) was used to screen a two-
hybrid mouse brain cDNA library. Among the positive clones, a portion of the RCC1 
homology domain of Protein Associated with Myc (PAM, residues 551-874) was 
identified as a potential interactor of KCC2-CT.  These 323 amino acids are a relatively 
small portion of the entire PAM protein (Figure 9).  This portion of PAM is located in a 
region similar to the Regulator of Chromatin Condensation 1 domain, or RCC1 domain. 
As its name suggests, the RCC1 domain was first characterized in the RCC1 protein for 
its cell cycle related effects in the nucleus.  The RCC1 protein binds to DNA and acts as a 
regulator for the initiation of chromosome condensation by catalyzing the exchange of 
guanine nucleotides on Ran GTPase (Ohtsubo et al., 1989; Bischoff and Ponstingl, 1991).  
X-ray crystallography of human RCC1 protein demonstrated that the structure of RCC1 
consists of a seven-bladed propeller formed by internal repeats of 51 to 68 amino acid 
residues per propeller blade.  The residues of RCC1 are not conserved in comparison to 
the WD-40 repeats found in the similarly shaped beta subunit of the heterotrimeric G-
proteins.  However, this propeller blade structure is in general highly similar, and could 
potentially indicate an evolutionary conservation of the propeller structure among 
superfamilies of GTP-binding proteins (Renault et al., 1998). 
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Figure 9. RCC1/PAM clone compared to full length PAM and homologues.  
A. The portion of PAM pulled from the KCC2-CT yeast two-hybrid screen is shown 
in relation to full length PAM.  Full length PAM and its various domains are 
depicted, along with PAM homologues in Danio rerio (Esrom), Drosophila 
(highwire), and C. elegans (rpm-1).  B.  Phylogenetic tree depicting similarities 
between proteins.  Figure compiled and adapted from Schaefer et al., 2000 and 
D'Souza et al., 2005.
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RCC1-like domains have been found in several other cytoplasmic proteins besides 
PAM.  One such protein is alsin, the product of the ALS2 gene.  Mutations in ALS2 are 
predominantly linked to a juvenile-onset form of amyotrophic lateral sclerosis (ALS) and 
juvenile primary lateral sclerosis (PLS). Alsin contains three domains with GTPase 
function, one of which is an N’-terminal RCC1 domain.  Several of the aforementioned 
ALS2 mutations cause a short form of the alsin protein, prematurely ending the protein in 
the middle of the RCC1 domain and thus deleting the other GTPase domains (Hadano et 
al., 2001; Yang et al., 2001; Gros-Louis et al., 2006).   In the cell, alsin plays many roles, 
not only in protein scaffolding and trafficking, but most significantly as an activator of 
rab/rac-mediated signaling pathways which control endocytosis, macropinocytosis, 
protein transport and neurite outgrowth and survival (Otomo et al., 2003; Tudor et al., 
2005; Devon et al., 2006; Hadano et al., 2006; Jacquier et al., 2006; Hadano et al., 2007; 
Kunita et al., 2007). Alsin’s RCC1 domain is responsible for alsin distribution in the 
cytoplasm, and the RCC1 domain also acts as a binding site for several proteins 
(Yamanaka et al., 2003; Hadano et al., 2007). For instance, the RCC1 domain of alsin 
binds to glutamate receptor associated protein GRIP1, and alsin has been functionally 
linked to AMPA receptor distribution and susceptibility to glutamate toxicity in neurons 
(Lai et al., 2006). 
Another RCC1-domain containing protein is Retinitis Pigmentosa GTPase 
Regulator protein, or RPGR. Individuals with X-linked retinitis pigmentosa, a severe 
form of macular degeneration, were found to have several in-frame deletions and 
nonsense and missense mutations clustered in the RCC1 region of the RPGR gene 
(Meindl et al., 1996; Buraczynska et al., 1997; Bauer et al., 1998; Miano et al., 1999; 
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Vervoort et al., 2000; Vervoort and Wright, 2002; Jin et al., 2005; Neidhardt et al., 2007).  
Later investigations into RPGR interactors showed that several proteins bound to RPGR 
though this RCC1 domain, such as the delta subunit of the photoreceptor-localized cyclic 
GMP phosphodiesterase (PDEδ), and several microtubule motor proteins localized to the 
cilia of photoreceptor cells (Linari et al., 1999; Roepman et al., 2000; Khanna et al., 
2005).  Additionally there is data demonstrating that the RPGR - RCC1 domain can 
independently traffic from basal to ciliary membranes after ciliogenesis in MDCKII cells 
(He et al., 2008). Collectively, this data demonstrates that the importance of the RCC1 
domain for protein-protein interactions, and possibly for protein transport and 
localization within the cell.  
 
PAM background 
PAM is a very large protein, with an estimated length of 4641 amino acids, and 
many groups report a molecular weight estimate of 510 kiloDaltons (Guo et al., 1998). 
One group has recently reported two molecular weights of PAM, an approximately 410 
kDa form unique to embryonic rat tissues and rat-derived cell lines, and a 350 kDa which 
is the most prominent isoform in the postnatal and adult stages (Santos et al., 2006). PAM 
has several distinct protein domains (Figure 9). As aforementioned, near the N-terminus 
of the protein is a domain with high homology to the Regulation of Chromatic 
Condensation domain.  This domain has a characteristic seven-bladed propeller structure, 
and in PAM this characteristic 7-fold repeat is retained, but divided in half by a 134 aa 
sequence.  PAM also has two signature 91 aa repeated sequences, termed the 
PAM/Highwire/RPM-1 (PHR) repeats.  Closer to the C-terminus is the myc-binding 
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domain.  Alternative splicing leads to six isoforms of this particular region, and affects 
binding affinity to myc. In the extreme C-terminus, two C2H2 domains are clustered near 
a RING zinc-finger domain, a domain characteristic of E3 ubiquitin ligase proteins (Guo 
et al., 1998; Peterson et al., 2002; Burgess et al., 2004). Given the size of this protein, and 
its many specialized domains, it is likely that PAM plays a part in many physiological 
roles in the cell -- an idea supported by the variety of findings about PAM function which 
have since been reported in the research literature. 
PAM (also known as Phr1 (Burgess et al., 2004) or MycBP2 in GenBank) was 
originally characterized as a myc binding protein (Guo et al., 1998).  However, later 
studies have shown that PAM is found in the cytosol during M and G1 phases of the cell 
cycle (Scholich et al., 2001). In neurons, it has been described as having subcellular 
localization in soma, axons and dendrites (Murthy et al., 2004) however, it is widely 
expressed and present in both neuronal and non-neuronal cell types.   
Several factors made PAM an intriguing potential candidate interactor with 
KCC2. One example is that PAM and KCC2 have an interesting overlap in spatial and 
temporal expression. In mice, both PAM and KCC2 undergo developmental upregulation 
during the first two weeks after birth (Yang et al., 2002). Additionally, PAM is highly 
expressed, and developmentally upregulated in the pyramidal cells of the hippocampus, 
granule cells of the dentate gyrus and cerebellum, as well as Purkinje cells of the 
cerebellum — regions in which KCC2 likewise has high levels of expression.  
Furthermore, both PAM and KCC2 have been linked in having a role in the spinal 
nociceptive pathway (Coull et al., 2003; Ehnert et al., 2004). 
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Later reports of mice with a disruption in the PAM/Phr1 gene likewise increased 
our interest in this protein.  One such report came from an analysis of the piebald deletion 
complex in mouse chromosome 14. These mice have chromosomal abnormalities 
surrounding the endothelin B receptor. PAM/Phr1 was identified as a candidate gene in 
this region contributing to the piebald phenotype (Peterson et al., 2002).  Mice with a 
deletion in the Phr1 gene have a similarity to the KCC2 knockout mouse phenotype, in 
that after birth they both exhibit respiratory distress and subsequently, death.  This 
respiratory distress is in part attributed to incomplete sensory innervations of the 
diaphragm muscle, abnormal synapses of the phrenic nerve on the diaphragm, and 
dysmorphic synapses on intercostal muscles (Burgess et al., 2004). 
Recently, two groups have independently published studies on the role of 
PAM/Phr1 in mice. In the first report, Bloom et al describe that constitutive Phr1 
knockout mice, like the piebald mice, do not begin breathing and die at birth, and have 
aberrant phrenic nerve innervations of the diaphragm. Additionally, the Phr1 mice lack 
innervation of the thalamus by retinal nerves. In the brain, the anterior commissure is 
absent, the corpus callosum is narrower, and there is a significant decrease in GABAergic 
neurites (but not cell bodies) as compared to control mice.   
Many brain morphology defects present in the constitutive knockout, including 
enlarged lateral ventricles, dysmorphic hippocampi and narrow corpus callosi, carried 
over to a conditional knockout with Phr1 function deleted in excitatory neurons of the 
cortex and hippocampus. Further analysis suggests that these defects are due to cortical 
neurons losing their ability to project their axons. In western blot analyses, they observe 
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no appreciable difference in DLK protein in these mice.  In the fly and worm, Highwire 
and RPM-1 downregulate DLK through ubiquitination (Bloom et al., 2007). 
However, another group also studied PAM/Phr1 function in mice after it was 
identified as a candidate gene for neurodevelopment regulation in a forward genetic 
screen in mice with motor axon projection defects. The Magellan mutation, which inserts 
a stop codon in PAM upstream of the zinc finger domains, causes extensive errors in 
motor and sensory neuron axon growth, particularly at major axonal choice points. They 
further localized PAM as associating with the tubulin cytoskeleton in the axon, but not in 
normal growth cones. They additionally used siRNA knockdown of Phr1 in neurons, and 
showed that neurons in culture phenocopied the axonal deficits shown in the Magellan 
mice. Subcellular immunostaining analysis of DLK expression shows that Magellan mice 
have upregulated amounts of DLK protein, and the authors suggest that PAM does in fact 
target DLK for ubiquitination.  The authors also report that application of BDNF to 
Magellan mutant neurons leads to enhanced axonal branching, and they suggest that a 
shift in PAM to the distal end of the neuron may cause synapse formation when the 
proper axonal target is reached (Lewcock et al., 2007). 
Studies of PAM function suggest that this protein has many varied functions in 
the cell, as is fitting for a protein of such an enormous size, with many different protein 
motifs/domains, and with ubiquitous expression.  One report of autoantibodies in 
schizophrenics identifies anti-Protein Associated with Myc antibodies present in patient 
serum (Balakrishnan et al., 2003). Scholich et al demonstrate that the N-terminal RCC1 
domain of PAM, due to its similar structure to Gαi and G-βγ proteins, can function as an 
inhibitor of adenylyl cyclases, specifically ACI, ACV, ACVI and ACVII  isoforms 
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(Scholich et al., 2001).  Sphingosine-1-phosphate, a GPCR ligand and signaling factor, 
plays a role in translocating PAM to the membrane to induce this adenylyl cyclase 
activity (Pierre et al., 2004). A C-terminal portion of PAM encompassing the RING zinc 
finger domain has been reported to bind on an SH3 domain on tuberin, a protein encoded 
by TSC2, a gene mutated in the human disease Tuberous Sclerosis (Murthy et al., 2004). 
 
Homologues of PAM in other species 
PAM also initially intrigued us as a potential interactor due in part to the 
phenotypes of PAM homologues mutants in the worm and fly.  PAM has high homology 
to Highwire (Hiw) in Drosophila  (Wan et al., 2000), and Regulator of Presynaptic 
Morphology 1 (RPM-1) in C. elegans (Schaefer et al., 2000; Zhen et al., 2000). Hiw 
mutants show aberrant synaptic structures, in that they have an excess of presynaptic 
boutons at neuromuscular junctions (Wan et al., 2000). Two identified RPM-1 mutants 
were shown to have abnormal synaptic organization, with one reported loss of function 
mutation causing aberrant synapse formation at GABAergic neuromuscular junctions 
(Schaefer et al., 2000; Zhen et al., 2000). Studies on these proteins, particularly Highwire, 
have strongly indicated their role in acting as a ubiquitin ligase, targeting presynaptic 
signaling proteins for degradation, and thus acting as a negative regulator of synaptic 
growth (DiAntonio et al., 2001; McCabe et al., 2004; Wu et al., 2005). The most recent 
PAM homologue to be identified is Esrom, present in zebrafish (Danio rerio). Like PAM, 
this vertebrate homologue is expressed widely throughout neurons and other cell types.  
Esrom mutants have defects in growth cone navigation during development, and also 
have defects in the projection of retinal axons, potentially due to misregulated 
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ubiquitination and degradation of tuberin, a tumor suppressor and intracellular signaling 
molecule (D'Souza et al., 2005; Hendricks et al., 2008). Esrom also controls the synthesis 
of pteridine, a signaling molecule in part necessary for yellow pigmentation (Le Guyader 
et al., 2005). These additional roles of Esrom, in comparison to Highwire and RPM-1, 
suggest vertebrate PAM homologues have more widespread and complex functions in 
higher organisms. 
 
Further exploration of KCC2 interaction with PAM 
As previously mentioned, PAM is a very large protein.  At the initiation of this 
project, no group had cloned full-length PAM. Thus, the project originally included 
attempts to clone full-length PAM. However, even using PCR protocols for large 
nucleotide spans, numerous mutations were introduced in the expanded-range PCR 
process.  Additionally, due to its large size, working with this full-length protein would 
be experimentally challenging, for instance in overexpression in mammalian expression 
vectors, precipitation/pull-down, transfer to membranes for Western blotting, etc.  Thus, 
the work described here was carried out using only the portion of PAM identified in the 
yeast two-hybrid library screen, from here on referred to as RCC1/PAM. 
Several classic methods were used to verify interaction between KCC2 and 
RCC1/PAM.  Additionally, examination of RCC1/PAM effect of KCC2 function was 
studied using radioisotope uptake assays in a mammalian cell system.  Cation-chloride 
cotransport by the CCCs has traditionally been assessed using 86Rb fluxes. 86Rb has a 
much longer half-life than isotopic K+ and is transported in the same manner as K+.  It 
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has been reported that KCC2 has a higher estimated affinity for external 86Rb (Michaelis 
constant (Km) = 5.2 ± 0.9 (SE) mM) than for external Cl- (Km >50 mM) (Payne, 1997). 
 
Methods  
Small-scale Y2H 
“Small scale” yeast two-hybrid transformations were used to ensure that 
RCC1/PAM alone did not activate yeast reporter genes. Such transformations are referred 
to as “small scale” to differentiate from the library-scale screens to identify novel protein 
interactors, but much of the methodology remains the same.  RCC1/PAM in the pACT2 
vector was first transformed into PJ69-4A yeast, and this strain was grown and 
maintained on -Leucine agar plates.  Then, empty pGBDUC2 vector was transformed 
into this yeast containing the RCC1/PAM-pACT2 plasmid.  Yeast transformations were 
plated on -Uracil, - Leucine plates, as a positive control to ensure successful expression 
of both plasmids in the yeast cells, as well as plated or restreaked on - Uracil, -Leucine, -
Histidine + 2 mM 3-amino-1,2,4-triazole plates to assess interaction.  
 
DNA constructs 
In order to create KCC2-CT fused to a GST fusion protein, KCC2-CT was 
subcloned into the pGEXT vector, directly following the GST sequence, and in the same 
translation frame.  For expression of RCC1/PAM in HEK cells, the mammalian 
expression vector pCDNA3 was used, and a HA tag was introduced for antibody 
recognition. 
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Western blotting 
For Western Blots, proteins were first denatured in sample buffer containing SDS 
and 5% beta-mercaptoethanol for 15 minutes at 72°C.  They were then loaded onto SDS-
polyacrylamide gels for electrophoresis, and transferred to polyvinylidene fluoride 
membrane (Millipore, Bedford, MA) using a semidry transfer apparatus. Membranes 
were then blocked in 5% non-fat milk/TBST for two hours at room temperature before 
incubation with antibody in milk/TBST overnight at 4°C. Antibody dilutions were as 
follows: KCC2, 1:1000 dilution; HRP-conjugated HA, 1:1000 (Roche, Indianapolis, IN). 
 
GST pull-down  
In order to create Glutathione S-Transferase (GST) fusion proteins, KCC2-CT 
cDNA was cloned into the pGEX4T1 vector (Pharmacia, Piscataway, NJ) inserted after 
the vector’s GST encoding sequence.  KCC2-CT-pGEX4T1 or empty pGEX4T1 (for 
GST only controls) were transformed into a protease-deficient strain of Escherichia coli. 
During growth, protein production was induced with isopropyl β-D-1-thiogalactopyrano- 
side (IPTG, 24mg/ml), and bacteria were lysed by freeze-thawing, sonication, and 
incubation with 20% Triton X-100. Lysates were centrifuged, and supernatants incubated 
with 50% Sepharose-Glutathione bead slurry. Following three spin/wash cycles, the pull-
down assay was performed as previously described (Piechotta et al., 2002), incubating 
GST protein-bound beads with HEK cell lysates. 
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Cell culture and transfection 
Human Embryonic Kidney (HEK293) or HEK293FT cells were maintained and 
routinely passaged in DMEM-F12 medium supplemented by 10% fetal bovine serum and 
1% Penicillin/Streptomycin (Invitrogen, Carlsbad, CA). Transfections were performed 
with Fugene 6 (Roche) on cells that were approximately 50-70 percent confluent. 
 
Coimmunoprecipitation 
Transfected HEK293FT cells (Invitrogen) were lysed with 1% Triton X-100 lysis 
buffer (150 mM NaCl, 10 mM Tris, 2 mM EDTA, 1% Triton X-100) containing protease 
inhibitors (Roche) for 30 min on ice. Lysates were scraped into 1.5 ml tubes and 
microcentrifuged for 10 min at 14,000 rpm at 4°C. KCC2 was immunoprecipitated from 
the supernatant with 7 µl of polyclonal KCC2 antibody overnight at 4°C. Protein A-
Sepharose beads (Santa Cruz Biotechnology, Santa Cruz, CA), pre-washed with lysis 
buffer, were incubated with the supernatant for 2 hours at 4°C. Antibody-protein 
complexes were pulled down by centrifugation for 4 minutes at 4,000 rpm. Pelleted beads 
were subjected to three spin/washes with 1 ml lysis buffer, then resuspended in sample 
buffer containing 5% β-mercaptoethanol and denatured at 70°C for 20 minutes.   
 
Microsome preparation 
Cells grown in 100-mm dishes were scraped in sucrose solution (0.32 M sucrose, 
2 mM EDTA, 2.5 mM β-mercaptoethanol, 5 mM Tris-Cl, pH 7.5, and protease 
inhibitors) and homogenized with a Teflon pestle for 20 strokes on ice. Cell debris was 
removed by centrifugation at 4,000 x g for 15 min. The recovered supernatant was then 
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centrifuged for 15 min at 9000 x g. The pellet from a final high-speed centrifugation 
(100,000 x g) was resuspended in 500 µl sucrose solution. 
 
RT-PCR and semi-quantitative RT-PCR 
In order to confirm the presence of PAM in two potential model cell systems, 
HEK293 cells and oocytes, RT-PCR was used.  RNA was retrieved from HEK293 cells 
and oocytes using the QiaShredder and RNeasy Total RNA extraction kit (Qiagen, 
Valencia, CA).  RNA was also obtained using the Qiagen RNA extraction kit from mouse 
brain stored in liquid nitrogen, as a control.  RNA was then reverse transcribed using 
Superscript II reverse transcriptase (Invitrogen, Carlsbad CA) using random hexamer 
primers, and these cDNAs were then subject to PCR.  PCR primers for PAM were 
designed to amplify a 400 bp sequence based on the Celera mouse genome database, 
human genome sequence, or Xenopus ESTs. PCR samples were then run on agarose-TAE 
gels and visualized by ethidium bromide staining and exposure to UV light.  
Semi-quantitative RT-PCR was used to quantitate RNA levels in HEK293 cells.   
RNA obtained from transiently transfected HEK293 cells was used for reverse 
transcription, as described above.  PCR primers CC1 and CC2 were used to amplify a 
412 bp sequence of KCC2 cDNA.  Samples were taken out at various PCR cycles, as 
indicated in the figures, in order to monitor exponential cDNA amplification before 
reaching saturation. PCR samples were then run on agarose-TAE gels and visualized by 
ethidium bromide staining and exposure to UV light. 
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Table 3: PCR primers used in RT-PCR experiments 
Target Primer Name Primer Sequence  (5’ to 3’) 
rKCC2 CC1 AGGGCGGAAAGAAGAAGCCG 
 CC2 TCCCCACTGGCATCTTCTGCC 
human 
PAM xPAM-PCR1 AAATTTGTGGCCAAGGACAG 
 xPAM-PCR2 CAGAAGACTCTTGCCAAGATG 
Xenopus 
PAM xPAM-PCR1 AAATTTGTGGCCAAGGACAG 
 xPAM-PCR2 CAGAAGACTCTTGCCAAGATG 
mouse 
PAM xPAM-PCR1 AAATTTGTGGCCAAGGACAG 
 mPAM-PCR2 CAGAAGGCTCTTGCCAAGATG 
 
86Rb+ uptake 
In order to observe KCC2 activity, transfected HEK293 cells were used two days 
post-transfection for 86Rb+ uptake experiments. Cells were washed twice with room 
temperature isotonic Na+-free solution (150 mM NMDG-Cl, 5 mM KCl, 2 mM CaCl2, 
0.8 mM MgSO4, 5 mM glucose, 5 mM HEPES, pH 7.4) then preincubated for 15 or 20 
minutes with Na+-free solution plus 100 µM ouabain. Following preincubation, cells 
were then incubated with Na+-free solution containing ouabain and 86Rb+ at a 
concentration of 1 µCi/µl. Uptake was terminated by three washes with ice cold Na+-free 
solution. Cells were lysed with 500 µl 1N NaOH for one hour, and then neutralized with 
250 µl glacial acetic acid. 86Rb+ uptake was measured from 150 µl of cell lysate added to 
5 ml Biosafe II scintillation cocktail (RPI, Mount Prospect, IL). Protein quantitation of 
lysates was determined by Bradford assay (BioRad, Hercules, CA). Final measurements 
were calculated as pmoles K+ per µg protein per min. Statistical analyses were performed 
by One Way ANOVA and Tukey post-test using GraphPad Prism software. 
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Results 
Negative control of yeast two-hybrid tests of interaction 
One possibility contributing to false positives is the potential for the identified 
yeast clone to unspecifically activate the auxotrophy reporter gene.  Some candidate 
proteins isolated from libraries have been shown to bind to the Gal promoter region, thus 
independently functioning as a transcription factor for yeast auxotrophy genes used in 
clone selection.  In order to test this in the case of RCC1/PAM, RCC1/PAM-pACT2 was 
tested in a small-scale yeast two-hybrid transformation against the empty pGBDUC2 bait 
vector.  As shown in Figure 10, when plated on the double-dropout -Uracil, -Leucine 
plate as a control, the transformed yeast survives, indicating that both pACT2 and 
pGBDUC2 vectors have been successfully transformed into yeast cells.  However, when 
plated on the –Uracil –Leucine – Histidine +2-AT plates, no yeast growth is seen, 
indicating that RCC1/PAM-pACT2 does not act as an unspecific transcription factor at 
the Gal promoter region of PJ69-4A, and does not activate yeast reporter genes 
independent of interaction with KCC2-CT. 
 
KCC2-CT and RCC1/PAM interaction in GST pull-down assays 
The interaction between KCC2-CT and RCC1/PAM was confirmed using a GST 
pull-down assay. Lysates from HEK293 cells expressing HA-tagged RCC1/PAM were 
incubated with GST-KCC2-CT immobilized on GST-Sepharose beads. As seen in Figure 
11, only GST-KCC2-CT was able to pull-down RCC1/PAM (lane 2), whereas GST alone 
did not pull down RCC1/PAM. 
Figure 10. Negative control of RCC1/PAM in yeast two-hybrid.
The partial PAM clone tested in a small scale yeast two-hybrid transformation 
against the empty bait vector, pGBDUC2.  Left, restreak on -Uracil, -Leucine 
media (control plate); Right, -Uracil, -Leucine, -Histidine +AT media 
(experimental plate).
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Figure 11. GST pull-down assay demonstrates KCC2-CT binding to 
RCC1/PAM. 
Immunoblot using HRP-conjugated anti-HA antibody. Lanes 1-4: GST pull-
down assay using either purified GST or GST-KCC2-CT, incubated with 
HEK293 cell lysate transfected with either pCDNA3 alone or HA-tagged 
RCC1/PAM. Lanes 5 and 6: whole cell lysates of transfected HEK293 cells.
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CoIP demonstrates RCC1/PAM binding to full-length KCC2 
Coimmunoprecipitation assays were used to show that the partial PAM clone also 
forms a complex with full-length KCC2 in cells. The partial PAM clone was tagged with 
an HA epitope, and cotransfected into HEK293FT cells with either empty pCDNA3 
vector or full-length KCC2. Cell lysates were subjected to immunoprecipitation using the 
KCC2 antibody, and protein complexes isolated with Protein A-Sepharose beads. 
Immunoblotting with HA antibody showed that PAM-HA is immunoprecipitated with 
KCC2 (Figure 12, lane 4). However, no PAM-HA was pulled-down in the absence of 
KCC2 (Figure 12, lane 2). 
 
Presence of endogenous PAM in HEK cells 
PAM has been localized to many different cell lines, such as HeLa cells, and 
many tissue types. Thus, it was anticipated that PAM would be expressed in HEK293 
cells and Xenopus laevis oocytes, two heterologous expression systems commonly used 
by the laboratory. The presence of PAM was confirmed by RT-PCR using RNA isolated 
from HEK293 cells, Xenopus oocytes, and mouse brain (control). Primers were designed 
based on previously reported sequences, or in the case of Xenopus, EST databases, to 
amplify a 400 bp sequence in the PAM cDNA.  As seen in Figure 13, PAM was detected 
in oocytes, HEK 293 cells, and mouse brain, but no signal was detected in the control 
(water only). 
 
 
50  kDa
35  kDa
30  kDa
    1        2        3          4             
RCC1-PAM-HA + pCDNA3 RCC1-PAM-HA + KCC2
Sup.        Co-IP Sup.         Co-IP


Figure 12. Coimmunoprecipitation of RCC1/PAM with full-length KCC2.  
Representative Western blot of co-immunoprecipitation experiments. HEK293 
cells were transfected with either RCC1/PAM alone, or KCC2 and RCC1/PAM. 
Anti-KCC2 antibody was used for immunoprecipitation, and HRP conjugated-
anti HA antibody was used for immunoblotting.
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Figure 13. RT-PCR demonstrates PAM is found in HEK293 cells.
RNA isolated from oocytes, HEK293 cells, and mouse
brain, was reverse-transcribed and PCR amplified using PAM-specific
primers. Note the presence of a ~390 bp PCR fragment in all three
samples and not in the negative control (water).
Xenopus laevis
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RCC1/PAM increases KCC2-mediated flux 
To assess the effect of PAM on KCC2 function, we cotransfected the RCC1/PAM 
fragment with full length KCC2 in HEK293 cells. Function of the cotransporter was 
assessed using unidirectional 86Rb+/K+ uptakes. Cells were transfected with KCC2 and/or 
RCC1/PAM two days prior to functional assays, and uptakes were measured at 6 min 
intervals over 30 min. As seen in Figure 14, KCC2 expression in HEK cells resulted in 
large Na+-independent K+ uptake, several fold greater than baseline (empty pCDNA3 
transfected). Interestingly, coexpression of the partial PAM clone increased KCC2-
mediated flux.  
 
86Rb+ flux does not increase with GST coexpression 
 One possible explanation of this increase in KCC2-mediated flux is that 
coexpression of any protein results in unspecific upregulation in KCC2 activity. Thus, as 
an additional control, glutathione S-transferase (GST), which has a molecular weight of 
approximately 35 kDa was used as a similarly sized, non-relevant protein, for 
coexpression with KCC2.  In 86Rb+ uptake experiments, coexpression of GST did not 
result in an increase in KCC2 flux (Figure 15).  This supports the evidence that the 
increase in KCC2 activity seen with RCC1/PAM coexpression is specific to RCC1/PAM, 
and not merely an artifact resulting from expression of a small ~30 kDa protein. 
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Figure 14. RCC1/PAM increases KCC2-mediated flux in HEK293 cells.  
Unidirectional 86Rb+ uptake in HEK293 cells measured at six minute 
intervals over 30 minutes. Cells were transfected with either: KCC2 and 
RCC1/ PAM clone (filled circles, dotted line), KCC2 only (open diamonds, 
solid line), RCC1/PAM only (open circles/dashed line) or empty pCDNA3 
vector only (filled squares, dashed/dotted line). Graph shown is 
representative of three experiments.
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Figure 15. GST does not affect KCC2 activity.
HEK293 cells were transfected with KCC2 alone, KCC2 and
RCC1/PAM, or KCC2 and GST. KCC2 uptake activity was measured
using unidirectional Rb uptake after 10 minutes of incubation with
Rb . ** = < 0.01 (ANOVA, Tukey post-test).
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RCC1/PAM effect on KCC2 protein  
To account for the increased KCC2 flux, we first considered the possibility that 
RCC1/PAM affects the amount of functional KCC2 protein. To quantitate the KCC2 
protein levels, we prepared HEK293 cell microsomal fractions to enrich for membrane-
associated proteins. Microsomes were subjected to Western blot analysis, and probed 
with anti-KCC2 antibody or with anti-human transferrin antibody to control for 
unspecific effects by RCC1/PAM. As shown in Figure 16, KCC2 levels increased 
significantly when the cotransporter was coexpressed with RCC1/PAM. This effect is  
RCC1-specific, as transfections were controlled for amount of DNA by using empty 
pcDNA3 vector. 
 
RCC1/PAM effect on KCC2 RNA expression 
To determine whether the increased KCC2 protein expression by RCC1/PAM 
originates from increased transcription, we examined KCC2 RNA levels under the 
different transfection conditions. Using semi-quantitative RT-PCR with primers specific 
to KCC2, we showed that RCC1/PAM increases KCC2 RNA levels in HEK293 cells 
(Figure 17). 
160 kDa
105 kDa
KCC2  
RCC1/PAM-HA
pCDNA3 +
+
+
+
+
Figure 16. RCC1/PAM increases KCC2 protein in HEK293 cells. 
HEK293 cells were transfected with rKCC2-pCDNA3 plus empty 
pCDNA vector or rKCC2 plus RCC1/PAM. Total protein was subject 
to SDS-PAGE for Western blotting. Membrane was probed with 
anti-KCC2 antibody. Representative of three separate experiments. 
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Figure 17.  RCC1/PAM increases KCC2 RNA levels in HEK293 cells. 
RNA was isolated from transfected HEK293 cells, and RNA yield used for 
reverse transcription.  Resulting cDNA was then used for semi-
quantitative PCR with reactions taken out at indicated cycles and run on 
agarose-TAE gels.  
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Discussion 
Validation of interaction using additional in vitro methods 
The data in this section validates binding between RCC1/PAM and KCC2, as 
identified in the initial yeast two-hybrid library screen. First, the negative yeast two-
hybrid control with empty pGBDUC2 vector demonstrates that RCC1/PAM does not 
intrinsically activate transcription of reporter genes in the yeast. Second, GST pull-down 
assays served as an in vitro method of testing RCC1/PAM interaction. As described, 
GST-KCC2-CT fusion protein can effectively pull down HA-tagged PAM expressed in 
HEK cells, whereas GST protein alone cannot. Finally, binding between full-length 
KCC2 and RCC1/PAM is demonstrated by coimmunoprecipitation of these proteins 
following heterologous expression in HEK293 cells. This test of protein interaction is 
important because it demonstrates that RCC1/PAM can interact with full-length KCC2, 
as the transporter would exist in its native state. Moreover, this experiment also has 
greater physiological relevance than the two-hybrid tests in the sense that, whereas two-
hybrid interaction takes place inside the nucleus, the protein-protein interaction of the 
coIP experiments takes place in a more natural cytoplasmic milieu. 
 
Interpretation of flux assays, and increased RNA and protein 
In order to explore the functional role of PAM and KCC2 interaction, 86Rb+ 
uptake assays on HEK293 cells were used to measure KCC2 activity. The experimental 
model tested compared expressed KCC2 activity alone or with RCC1/PAM.  The logic 
behind this was that, in lieu of having a full-length PAM clone to express, RCC1/PAM 
could be used as a dominant negative PAM isoform which would compete with 
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endogenous PAM for docking on the KCC2-CT. PAM expression is reported in many 
different cell lines, thus it was expected that it would be present in HEK293 cells. To 
verify this, RT-PCR was used on HEK cell RNA, and this indeed verified PAM was 
expressed in the HEK293 cells as well. 
HEK cells demonstrated a baseline amount of 86Rb+ transport over time, and 
expression of RCC1/PAM alone did not change flux (Figure 14).  KCC2 expression 
increased 86Rb+ uptake significantly above baseline, and KCC2 coexpression with 
RCC1/PAM even further increased 86Rb+ uptake, significantly more than KCC2 alone.  
In order to rule out the idea that the cotransfection itself caused a flux increase, GST was 
used as a non-specific protein control, and it did not, in fact, cause an increase in KCC2 
flux.  This suggests that RCC1/PAM, specifically, is responsible for the increase in 
KCC2 activity, and not an artifactual effect of cotransfecting two proteins. 
There are many points at which RCC1/PAM could be affecting KCC2-mediated 
flux.  One possibility is that RCC1/PAM is changing whole-cell levels of the 
cotransporter by affecting transcription and/or translation. Alternatively, RCC1/PAM 
could be changing cell surface levels of the cotransporter (either through protein 
trafficking and insertion into the membrane, or through endocytosis and/or degradation).  
Finally, RCC1/PAM could be acting at the cell surface to change cotransporter activity, 
such as through allosteric modification of the transporter, or post-translational 
modifications like dephosphorylation. 
In order to answer these questions, both RNA and protein levels of KCC2 were 
quantitated. Not only was there an overall increase in KCC2 protein, but there was also 
an increase in KCC2 RNA. The effect of RCC1/PAM on KCC2 transcription thus could 
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account for the increased KCC2 flux observed in Figure 14.  This result was puzzling, in 
light of the fact the initial link between RCC1/PAM and KCC2 stemmed from identifying 
a protein-protein interaction. It is however possible that RCC1/PAM could affect KCC2 
independent of this transcriptional effect. RCC1/PAM could affect transcription, but 
could also affect KCC2 function through its binding to the carboxyl terminus tail. One 
way to test this hypothesis is to specifically disrupt RCC1/PAM binding to the carboxyl 
terminus by creating a mutated KCC2 which disabled binding to the KCC2-CT. In the 
next chapter, the yeast two-hybrid system is employed once again in an attempt to 
elucidate the binding site of RCC1/PAM on KCC2, and thus create a binding deficient 
KCC2 construct. 
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CHAPTER IV 
 
IDENTIFICATION OF RCC1/PAM BINDING SITES ON KCC2 
 
Introduction 
Why build a binding site mutant? 
As discussed in the previous chapter, significant evidence exists that RCC1/PAM 
binds to KCC2.  The increase in KCC2 activity seen when cotransfecting RCC1/PAM 
with KCC2 appeared promising, especially considering that the effect was specific to 
RCC1/PAM and not to GST, a similarly-sized protein.  However, further investigation 
into the cause of this increased KCC2 activity demonstrated that KCC2 RNA levels 
likewise increased in the presence of RCC1/PAM. Thus, a new strategy had to be utilized 
in order to tease apart and isolate the functional effect of the RCC1/PAM and KCC2 
protein-protein interaction. 
The Delpire laboratory has had success in using the yeast two-hybrid system to 
identify specific protein binding regions, even down to amino acid residues responsible 
for binding. The SPAK binding motif present on KCC3 and NKCC1was identified by 
using yeast two-hybrid, and this motif has been identified in many other SPAK binding 
partners (Piechotta et al., 2002; Delpire and Gagnon, 2006). Thus, this same methodology 
was employed in order to further characterize the binding site of RCC1/PAM on KCC2. 
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RXR motifs 
As further described in the Results and Discussion sections of this chapter, a 
putative RXR motif is present in the KCC2-CT.  This is particularly interesting because 
the RXR motif is a trafficking signal which regulates retention and release from the 
endoplasmic reticulum (ER). This motif was first identified in the carboxyl terminus of 
the ATP-sensitive K+ channel. The K+ channel motif RKR is masked in tetrameric 
assembly of the K+ channel, which then allows release of the complete assembled 
channel complex to the ER.  Conversely, exposed RXR motifs result in ER retention, 
thus preventing incomplete partial channel complexes from being expressed at the cell 
surface (Zerangue et al., 1999).  This ER retention signal has since been identified in a 
variety of other membrane transport and receptor proteins, such as the NMDA NR1 
subunit, GABAB receptor , and CFTR transporter (Margeta-Mitrovic et al., 2000; Scott et 
al., 2001; Hegedus et al., 2006). It has been demonstrated that RXR motif-mediated ER 
retention can be suppressed by PKC phosphorylation or alternative splicing to introduce 
an adjacent type-1 PDZ domain (Scott et al., 2001). Thus, the RXR motif is a versatile 
mechanism for mediating ER retention, and consequently, cell-surface expression of 
membrane proteins. Clearly, this domain is a particularly interesting feature of the KCC2-
CT, especially considering the possibility that PAM may bind to this domain and act as a 
chaperone protein. 
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Methods 
Small-scale yeast two-hybrid 
The yeast two-hybrid system was used to test interaction between RCC1/PAM 
and various truncations and mutated isoforms of the KCC2-CT. These tests against two 
known proteins are referred to as small-scale transformations, so as to differentiate from 
the library-scale screen to identify novel protein interactors.  However, much of the 
methodology remains the same.  Many variations of the KCC2-CT were all to be tested 
against RCC1/PAM, so therefore RCC1/PAM in pACT2 vector was first transformed 
into PJ69-4A yeast, and this strain was maintained, as previously described, on -Leucine 
agar plates.  Then, regions of the KCC2-CT of varying lengths were subcloned into 
pGBDUC2 vector, and then transformed into yeast containing the RCC1/PAM-pACT2 
plasmid.  Yeast transformations were plated on -Uracil, - Leucine plates, as a positive 
control ensuring a successful expression of both plasmids in the yeast cells, and plated or 
restreaked on - Uracil, -Leucine, -Histidine +2AT plates to assess interaction.  
Small-scale yeast two-hybrid experiments involving KCC1, KCC3, and KCC4 
were done in the same fashion, with the cotransporter regions isolated from cDNA by 
PCR, then inserted into the pGBDUC2 vector for yeast two-hybrid assays against 
RCC1/PAM-pACT2 in PJ69-4A yeast. 
 
DNA constructs 
Truncations of the KCC2-CT were generated by using restriction sites located in 
the carboxyl terminus, as well as PCR and Expand Long PCR (Roche, Indianapolis, IN) 
with overhangs allowing for subcloning into the desired vectors. For sequences under 40 
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base pairs in length, annealed oligonucleotides were designed, again with overhangs to 
allow for subcloning into yeast two-hybrid vectors.   To generate the RXR KCC2 mutant, 
a 513 bp SphI-ClaI fragment consisting of the last 56 amino acids of rat KCC2, some 
3’UTR and some polylinker were subcloned into a modified pBSK vector containing a 
SphI restriction site. The codon encoding the second arginine (CGC) of the RXR motif 
was mutated into an alanine (GCC) using QuikChange (Stratagene, La Jolla, CA). After 
sequencing, the SphI-ClaI fragment was reintroduced into the wild type clone to produce 
the mutant KCC2 cDNA.  
 
 
Table 4: PCR primers and adapters for KCC2-CT truncation mutants as per Figure 18 
Construct Primer Name Primer Sequence  (5’ to 3’) 
Bait8 (b) B8S CGGAATTCCGGGGGGCAGAGAAGGAGTGGGG 
 B8A GAAGATCTTCAGTAGGTGTATGCTGAGATGTCGC 
Bait9 (c) B9S GCCAATTGATTACTGCAGAGGTGGAAGTCGTGG 
 B9A GAAGATCTTCAGGAGTAGATGGTGATGACCTC 
Bait6 (d) B6S CGGAATTCCACGACGGGGGCATGCTCATG 
 B6A CGGGATCCTTAGGGCATGTTGAGCAACAC 
Bait4 (e) B4 CGCAATTGTTGGTGTTGCTCAACATGCCC 
 B4A CGGGATCCTTAGGAGTAGATGGTGATGACCTC 
Bait4B (g) B4 CGCAATTGTTGGTGTTGCTCAACATGCCC 
 NG14 GCGTTACCTCTACTTTTGATGTACACTCCTAGGGC 
Bait4D (h) B4 CGCAATTGTTGGTGTTGCTCAACATGCCC 
 NG15 GGAGGGGCGTTGGCGTTACCTCTAACTCCTAGGGC 
Bait4E (i) NG13 CGGAATTCAACATGCCCGGGCCTCCCCGCAAC 
 NG14 GCGTTACCTCTACTTTTGATGTACACTCCTAGGGC 
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Table 5: Adapter oligonucleotides for KCC sequences used in Figure 19 
Construct Primer 
Name 
Primer Sequence  (5’ to 3’) 
Figure 19A   
KCC1 (a) K1PB1 AATTCCTGGTCCTACTGAACATGCCCGGCCCCCCTAAGAACAGTGAGGGTGAT
GAGAACTACATGTGAG
 K1PB2 GATCCTCACATGTAGTTCTCATCACCCTCACTGTTCTTAGGGGGGCCGGGCAT
GTTCAGTAGGACCAGG 
KCC2 (b) K2PB1 AATTCCTAGTTTTGCTCAACATGCCCGGGCCTCCCCGCAACGCCAATGGGGAT
GAAAACTACATGTGAG 
 K2PB2 GATCCTCACATGTAGTTTTCATCCCCATTGGCGTTGCGGGGAGGCCCGGGCAT
GTTGAGCAAAACTAGG 
KCC3 (c) K3PB1 AATTCCTGGTTTTGTTGAATATGCCAGGACCACCCCGGAACCCTGAAGGTGAT
GAAAACTACATGTGAG 
 K3PB2 GATCCTCACATGTAGTTTTCATCACCTTCAGGGTTCCGGGGTGGTCCTGGCAT
ATTCAACAAAACCAGG 
KCC4 (d) K4PB1 AATTCCTGGTCCTGCTGAATATGCCAGGCCCCCCAAAAAGTCGGCAGGGGGAC
GAGAACTACATGTGAG 
 K4PB2 GATCCTCACATGTAGTTCTCGTCCCCCTGCCGACTTTTTGGGGGGCCTGGCAT
ATTCAGCAGGACCAGG 
Figure 19B   
KCC3-
RXR (d) 
K3PB3 AATTCCTGGTTTTGTTGAATATGCCAGGACCACCCCGGAACCGTGAAGGTGAT
GAAAACTACATGTGAG 
 K3PB4 GATCCTCACATGTAGTTTTCATCACCTTCACGGTTCCGGGGTGGTCCTGGCAT
ATTCAACAAAACCAGG 
KCC2, 
RXRE (e) 
K2RXREf GAATTCTTGGTGTTGCTCAACATGCCCGGGCCTCCCCGCAACCGCGAAGGAGA
TGAAAACTACATGTGAG 
 K2RXREr GGATCCTCACATGTAGTTTTCATCTCCTTCGCGGTTGCGGGGAGGCCCGGGCA
TGTTGAGCAACACCAAGAATT 
KCC2, 
RXPN (f) 
K3RXPNf GAATTCCTGGTTTTGTTGAATATGCCAGGACCACCCCGGAACCCTAATGGTGA
TGAAAACTACATGTGAG 
 K3RXPNr GGATCCTCACATGTAGTTTTCATCACCATTAGGGTTCCGGGGTGGTCCTGGCA
TATTCAACAAAACCAGGAATT 
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Results 
KCC2-CT truncations narrow down RCC1/PAM binding site on KCC2-CT 
In order to isolate the functional effect of RCC1/PAM binding to KCC2-CT, and 
distinguish to from the influence of RCC1/PAM on KCC2 transcription, the binding site 
of RCC1/PAM on KCC2-CT was further characterized by creating truncation mutants of 
the KCC2-CT.  These were then tested in small-scale yeast two-hybrid transformations 
against the PAM library clone (Figure 18A-C). Using this method, a 20 amino acid 
stretch of the KCC2-CT, which retains the ability to bind RCC1/PAM, was identified 
(Figure 18A-C, g).  This 20 amino acid sequence did not fall within the 34 amino acid 
KCC2-specific region which has been reported to confer KCC2 activity in isotonic 
conditions, a feature unique to KCC2 as opposed to the other KCC isoforms (Mercado et 
al., 2006). 
 
Y1087A point mutant still retains binding to RCC1-PAM 
Located in this 20 amino acid stretch is a tyrosine residue, Y1087, which had 
previously been shown to be critical for KCC2 function via a mechanism independent of 
phosphorylation (Strange et al., 2000).  Hypothesizing that PAM binding to KCC2 might 
also involve this tyrosine residue, and thus be responsible for the phosphorylation-
independent control of KCC2 function, a subclone of KCC2-CT was made from a mutant 
KCC2 cDNA, in which this tyrosine residue was replaced with an alanine residue.  This 
Y1087A KCC2-CT construct was then used in a yeast two-hybrid assay to test for a 
change in binding.  However, as seen in Figure 18, RCC1/PAM binding to KCC2-CT 
was unaffected by this mutation (Figure 18A-C, k). 
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Figure 18. RCC1/PAM interaction narrowed down to 20 amino acids in 
the carboxyl terminus.  
A-C: Truncation mutants of KCC2-CT were used in small scale yeast two-
hybrid transformations with RCC1/PAM clone. 
A: Restreak on -Uracil, -Leucine media (control plate).  B: Restreak on 
-Uracil, -Leucine, -Histidine + AT media (experimental plate). 
C: Schematic/sequences of regions of KCC2-CT used for the truncation 
mutants.  Solid bar/plus sign represents a positive interaction; open bar/minus 
sign represents a negative interaction.  
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KCC alignment 
The four K-Cl cotransporters generally have highly conserved carboxyl-terminal 
tails.  Since the 20 amino acid sequence we identified did not overlap with the KCC2 
specific region, the sequence of the corresponding RCC1/PAM binding region in the 
three other cotransporters was analyzed. As shown in Figure 19A, the PAM-binding 
region of KCC2 is very similar to that of the other potassium-chloride cotransporters, 
differing only by a few amino acid residues. 
This similarity is advantageous in that these corresponding regions in the other 
cotransporters, tested in “small scale” yeast two-hybrid transformation assays, can thus 
elucidate the specific amino acid residues that are responsible for this protein-protein 
interaction. As shown in Figure 19A, the RCC1/PAM fragment only interacts with this 
region in KCC2, but not with the corresponding regions in the other K-Cl cotransporters. 
 
Presence of RXR motif in KCC2 and implications for RCC1/PAM binding 
One interesting feature highlighted by the sequence alignment of the KCCs is the 
presence of a RXR motif within this 20 amino acid region of KCC2.  Moreover, this 
motif is not present in the analogous sequences of the other cotransporters. As described 
earlier, this observation is particularly interesting because RXR motifs are known to 
function as ER retention signals.  Therefore, in order to explore the importance of the 
non-conserved residues and the RXR motif, single amino acid mutations were introduced 
into this region of both KCC2 and KCC3. Disrupting the motif by substituting the second 
arginine residue into an alanine (RXA) prevented binding to partial RCC1/PAM (Figure 
19B). However, introducing an RXR motif into this portion of KCC3 did not confer PAM  
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e: LVLLNMPGPPRNREGDENYME (KCC2, RXRE)
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Figure 19. KCC2 point mutant, KCC2-RXA, disrupts RCC1/PAM binding 
with the minimum 20 amino acid sequence.  
A: Small-scale yeast two-hybrid transformation testing interaction between 
RCC1/PAM against portions of other KCCs homologous to the minimum 
binding region in KCC2. Top, amino acid sequence alignment. Left, restreak on
 -Uracil, -Leucine media. Right, restreak on -Uracil, -Leucine, -Histidine + AT 
media. B: Small-scale yeast two hybrid transformation testing interaction 
between RCC1/PAM in pACT2, and various mutants of the minimum binding 
site in KCC2 and homologous region in KCC3. Top, amino acid sequence 
alignment. Rectangle denotes non-conserved residues between KCC2 and KCC3 
in the 20 amino acid region. Bold and underlined residues represent introduced 
point mutations.  Left, restreak on -Uracil, -Leucine media. Right, restreak on 
-Uracil, -Leucine, -Histidine + AT media.
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binding (Figure 19B). This suggests that binding was not only dependent on the RXR 
motif, but also on neighboring amino acid residues.  In support of this idea, introduction 
of a glutamic acid directly downstream of the RXR motif in KCC2 (thereby mimicking 
KCC3), was sufficient to disrupt PAM interaction with KCC2 (Figure 19B). 
 
Discussion 
Features of RCC1/PAM binding region on KCC2-CT 
Truncations of the KCC2-CT and small-scale yeast two-hybrid transformations 
effectively narrowed down the RCC1-PAM interacting region to rKCC2 residues 1069-
1088.  This 20 amino acid domain is located between the extreme C-terminus and the 
region unique to KCC2 which confers constitutive basal activity in isosmotic conditions 
(Mercado et al., 2006).  
The region of KCC2 encompassing this domain and the extreme C-terminus is 
known to be essential for cotransporter function. In addition to the putative RXR motif 
described earlier, the 20 amino acid peptide interacting with RCC1/PAM also contains an 
adjacent putative non-canonical type II Src homology domain 3 (SH3) binding sequence 
(φPxφPx+) (Barmashenko et al., 2005). SH3 domains are ubiquitous protein interaction 
modules that are involved in many types of protein-protein interactions.  They participate 
in linking membrane transporters and channels to the cytoskeleton (Choi et al., 2005; 
Tian et al., 2006), promote protein dimerization (Kristensen et al., 2006), and play a 
central role in multi-protein scaffolding (Roos and Kelly, 1998; Sheng and Kim, 2000; 
Xu et al., 2003).   However, the fact that all four sequences were identical for the 
MPGPP[R/K] SH3 putative binding sequence suggested that mutation of this domain 
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would not likely result in a disruption of binding between RCC1/PAM and KCC2.  This 
does not fully exclude, however, the possibility that this SH3 domain is somehow 
involved with KCC2 regulation, perhaps via binding to an unknown protein when PAM 
is not docked or binding to the KCC2-CT.  
 
Significance of RXR motif and residues necessary for RCC1/PAM binding 
Despite the high degree of conservation among the four K-Cl cotransporters, it is 
striking that only the 20 amino acids from KCC2 interacted with the RCC1 domain of 
PAM in our yeast two-hybrid assay. RCC1/PAM did not promote yeast survival in small-
scale yeast two-hybrid tests against the highly homologous region of KCC1, KCC3, and 
KCC4.  The fact that the RXR motif is unique to KCC2 in this region led to the 
hypothesis that perhaps RCC1/PAM is masking of the motif to allow protein release from 
the ER.  In other RXR-domain containing membrane transport proteins, masking of the 
RXR motif is done by homomeric or heteromeric subunits, or by ER chaperone proteins 
(Yuan et al., 2003; Hermosilla et al., 2004; Vivithanaporn et al., 2006).  Mutagenesis 
analysis (Figure 19) revealed that mutating the RXR motif in KCC2 to RXA disrupted 
RCC1/PAM binding.  Mutating the KCC3 sequence to contain an RXR motif did not, 
however, confer binding to RCC1/PAM.  Additionally, mutating the asparagine (N) 
residue directly after the RXR motif in KCC2 also disrupted RCC1/PAM binding.  Taken 
together, these experiments indicate a role for surrounding residues.   
Identification of this pattern of amino acid residues is particularly interesting in 
light of the previous report of adenylyl cyclases binding and being inhibited by PAM, in 
particular by the RCC1 domain (Scholich et al., 2001).  This interaction was discovered 
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in a yeast two-hybrid screen using adenylyl cyclase V as a bait protein.  An alignment of 
the 20 amino acid region of KCC2 with adenylyl cyclase V shows conservation of some 
key residues (Figure 20).  This pattern is also present in ACVI, another isoform inhibited 
by PAM, but is not present in ACII, which is unaffected by PAM.   It is possible that 
there is a common regulation pathway linking these proteins. 
The yeast two-hybrid experiments presented here demonstrate the identification 
of a point mutation which disrupts binding in this particular 20 amino acid region of 
KCC2-CT.  As the ultimate goal is to understand more about the functional effect of 
PAM binding to the KCC2-CT, the next chapter examines the functional effects of this 
point mutation in full-length KCC2, in comparison to wild type KCC2. 
KCC2: P R N R N G D E N Y M
ACV: A R E R R N D E L Y Y
A R E R R N D E L Y YACVI:
A R L S K N E E L Y HACII: (874)
(962)
(1055)
(1078)
R x R
Figure 20. Alignment of homologous portions of adenylyl
cyclases V, VI, and II with KCC2.
Numbers in parentheses represent the position of the first amino acid.
Yellow boxes indicate amino acid conservation.
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CHAPTER V 
 
KCC2 POINT MUTANT AND IMPACT ON KCC2 RCC1/PAM INTERACTION 
 
Introduction 
Further examination of the KCC2 point mutant in context 
In the experiments described in Chapter III, RCC1/PAM binding to the KCC2 CT 
was validated. Coexpression of RCC1/PAM with KCC2 in HEK293 cells demonstrated 
RCC1/PAM’s ability to upregulate KCC2 RNA and protein levels, and thus alter KCC2-
mediated flux.  However, taking into consideration that PAM is a candidate binding 
partner with KCC2, upregulation of KCC2 transcription is particularly puzzling.  So, in 
order to create a targeted disruption of RCC1/PAM binding on the KCC2-CT, 
characterization of the RCC1/PAM binding site was performed.  As described in Chapter 
IV, RCC1/PAM binding on the KCC2-CT was narrowed down to 20 amino acids.  
Furthermore, this led to identification of an arginine residue, unique to KCC2 and located 
in a putative RXR motif, which, when mutated to alanine, disrupts interaction with these 
20 amino acids.  In this chapter, this point mutant is introduced into full-length KCC2 
and used for several experiments which recapitulate the studies of RCC1/PAM 
coexpression in Chapter III.  The effect of RCC1/PAM on mutant KCC2 RNA and 
protein expression, as well as mutant KCC2 activity, is examined alongside wild type 
KCC2 in order to elucidate the functional effects of PAM binding to the KCC2-CT. 
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N-ethylmaleimide and KCC2 activity 
N-ethylmaleimide (NEM) is a known activator of K-Cl cotransport in many cell 
types (Lauf and Theg, 1980; Adragna et al., 2002; Lauf et al., 2006; Gagnon et al., 2007), 
including flux by KCC2 heterologous expressed in HEK293 cells (Gillen et al., 1996; 
Payne, 1997). It has been shown that okadaic acid added prior to NEM inhibits activation 
of transport. Thus, NEM is believed to act on KCC2 activity via 
phosphorylation/dephosphorylation pathways (Figure 21).  Total net dephosphorylation 
leading to KCC2 stimulation may be caused by NEM directly acting to dephosphorylate 
KCC2, or through kinase inhibition, although this is not known (Jennings and Schulz, 
1991).  NEM is, however, a reliable activator of KCC2 activity.  Here, NEM stimulation 
is used in flux assays in order to tease apart effects of RCC1/PAM specific to 
RCC1/PAM binding on the KCC2 carboxyl terminus, as opposed to the aforementioned 
RNA and protein upregulation effects which are not due to the protein interaction 
originally identified.   
NEM
PP1A
*P
*P
Kinase
KCC2 KCC2
kinase?
?
?
?
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Figure 21.  NEM in KCC2 stimulation pathway. 
N-ethylmaleimide (NEM) is a potent activator of KCC2 flux activity.  It is 
unknown exactly how NEM activates KCC2 activity, but it likely causes a net 
dephosphorylation of the cotransporter.  NEM could accomplish this by 
affecting upstream phosphorylation/dephosphorylation pathways, either 
activating protein phosphatases or inhibiting a regulatory kinase of KCC2. 
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Methods 
Western blotting 
In Western Blot assays, proteins were separated by SDS-polyacrylamide gel 
electrophoresis and transferred to polyvinylidene fluoride membrane (Millipore, Bedford, 
MA) using a semidry transfer apparatus. Membranes were blocked in 5% non-fat 
milk/TBST for two hours at room temperature before incubation with antibody in 
milk/TBST overnight at 4°C. Antibody dilutions: KCC2, 1:1000 dilution; HRP-
conjugated HA, 1:1000 (Roche, Indianapolis, IN), human transferrin receptor, 1:2500 
(Invitrogen, Carlsbad, CA). 
 
Coimmunoprecipitation 
In order to assess the effect of the KCC2 mutation when introduced into full-
length KCC2, coimmunoprecipitation assays were used.  Once again, transfected 
HEK293FT cells (Invitrogen) were lysed with 1% Triton X-100 lysis buffer (150 mM 
NaCl, 10 mM Tris, 2 mM EDTA, 1% Triton X-100) containing protease inhibitors 
(Roche) for 30 minutes on ice. Lysates were then scraped into 1.5 ml tubes and 
microcentrifuged for 10 minutes at 14,000 rpm at 4°C. KCC2 was immunoprecipitated 
from the supernatant with 7 µl of polyclonal KCC2 antibody overnight at 4°C. Protein A-
Sepharose beads (Santa Cruz Biotechnology, Santa Cruz, CA), pre-washed with lysis 
buffer, were incubated with the supernatant for 2 hours at 4°C. Antibody-protein 
complexes were pulled down by centrifugation for 4 minutes at 4,000 rpm. Pelleted beads 
were subjected to three spin/washes with 1 ml lysis buffer, then resuspended in sample 
buffer containing 5% β-mercaptoethanol and denatured at 70°C for 20 minutes.   
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Semi-quantitative RT-PCR 
As described before, semi-quantitative RT-PCR was used to quantitate KCC2 
RNA levels in transiently transfected HEK293 cells. RNA was retrieved from HEK293 
cells using the QiaShredder and QiaPrep Total RNA extraction kit (Qiagen, Valencia, 
CA).  RNA was then reverse transcribed with Superscript II reverse transcriptase 
(Invitrogen, Carlsbad CA) using random hexamer primers. PCR was performed on the 
resulting cDNA, again using primers CC1 and CC2 to amplify a 412 bp region of KCC2.  
Samples were taken out at various PCR cycles, as indicated in the figures, in order to 
monitor exponential cDNA amplification before reaching saturation. PCR samples were 
then run on agarose-TAE gels and visualized by ethidium bromide staining and exposure 
to UV light. 
 
Biotinylation of proteins 
In order to look at cell surface expression of proteins, biotin tagging and pull-
down was performed with NHS-S-S-sulfobiotin and NeutrAvidin beads (Pierce).  Using a 
protocol adapted from Daniels and Amara (Daniels and Amara, 1998) cells were washed 
in ice cold 1x PBS, then incubated with 1mg/ml to 2mg/ml biotin, the maximum 
recommended concentration, for 25 minutes at 4°C with gentle agitation.  Cells were 
quenched by two washes, followed by a 25 minute incubation in glycine quench buffer 
(100mM Glycine in 1x PBS), again at 4°C with gentle agitation. Following three washes 
in 1x PBS, cells were scraped, lysed (1% Triton X-100, 150 mM NaC1, 5 mM EDTA, 50 
mM Tris, pH 7.5) and centrifuged as earlier described to clear DNA/unsolubilized 
fraction.  Supernatant containing solubilized proteins was then incubated with 
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NeutrAvidin beads for one hour at 4°C in an end-over-end rotator.  Pull-down of beads 
was performed by four spin-wash steps, twice in high-salt wash buffer (0.1% TritonX-
100, 500mM NaCl, 5mM EDTA, 50mM Tris pH 7.5), followed by twice in no salt buffer 
(50mM Tris, pH 7.5).  Proteins were eluted from beads by addition of sample buffer plus 
5% β-mercaptoethanol and denaturing, as previously described. 
 
86Rb+ uptake 
Once again, the 86Rb+ uptake assay described earlier was used to measure KCC2 
activity.  As indicated in figures, flux assays were done with HEK293 cells transfected 
with either wild type KCC2 or KCC2-RXA, and either RCC1/PAM or empty pCDNA3 
vector.  N-ethylmaleimide (NEM) stimulation was performed using NEM dissolved in 
DMSO, and then applied to cells in a final concentration of 1mM, for a total of 15 
minutes.  As a control, vehicle (DMSO) alone was used in the non-stimulated, NEM-free 
flux conditions. 
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Results 
Effect of RCC1/PAM on KCC2-RXA mutant protein and RNA levels 
To assess the effect of preventing RCC1/PAM interaction with the C-terminal 
region, the RXA mutation described in Chapter IV was introduced into full-length KCC2.  
This clone is thus referred to as KCC2-RXA.  KCC2-RXA was transfected into HEK293 
cells in the presence or absence of the RCC1/PAM fragment, and compared to wild type 
KCC2, also in the presence and absence of RCC1/PAM, as a control. Interestingly, 
coexpression of RCC1/PAM with KCC2-RXA resulted in increased KCC2 RNA and 
protein levels, similar to those observed with wild type KCC2 (Figure 22). 
 
Coimmunoprecipitation of RCC1/PAM and KCC2-RXA 
Coimmunoprecipitation experiments were also performed on HEK cells 
expressing both KCC2-RXA and HA-tagged-RCC1/PAM.  As shown in Figure 23, 
immunoprecipitation of KCC2-RXA with KCC2 antibody still results in pull-down of 
RCC1/PAM.  Thus, it seems that the PAM fragment also interacts elsewhere on KCC2, 
and not only the carboxyl tail 20 amino acid region identified by yeast two-hybrid. 
 
KCC2-RXA transport activity 
86Rb+ uptake assays were used to measure KCC2-mediated transport in HEK293 
cells transfected with wild type KCC2 and mutant KCC2-RXA.  As shown in Figure 24, 
KCC2-RXA retained flux activity, with a significant increase in flux over the pCDNA3 
alone baseline and no significant decrease compared to wild type KCC2 activity. 
IB: KCC2
IB: hTR
KCC2
KCC2-RXA
RCC1/PAM
-
- -
-
- -
+
+ +
+ +
+
A.
Figure 22.  KCC2-RXA, like KCC2, has increased protein and RNA levels 
when cotransfected with RCC1/PAM.  
A: Microsome preparations were made from HEK293 cells transfected with 
rKCC2-pCDNA3 plus empty pCDNA vector (lane 1), rKCC2 plus 
RCC1/PAM pCDNA3 (lane 2), KCC2-RXA-pCDNA3 plus empty pCDNA 
vector (lane 3), and KCC2-RXA plus RCC1/PAM pCDNA3 (lane 4). Western 
blot was probed with anti-KCC2 antibody and anti-human transferrin receptor 
antibody. Representative of three separate experiments. B:  Semi-quantitative 
PCR was performed as described earlier, with the indicated HEK cell 
transfection conditions. 
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Figure 23.  Coimmunoprecipitation of RCC1/PAM with KCC2 and 
KCC2-RXA.  A: Representative Western blot of coimmunoprecipitation 
experiments. HEK293FT cells were transfected with either RCC1/PAM 
alone, KCC2 and RCC1/PAM, or KCC2-RXA and RCC1. KCC2 antibody 
was used for immunoprecipitation and HRP-conjugated anti-HA antibody 
was used for immunoblotting. B: Coimmunoprecipitation experiments 
were quantitated by measuring pixel intensity using ImageJ (NIH). Data is 
normalized to the negative control (RCC1/PAM only condition).
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 The activity of both wild type and mutant KCC2 was also examined in the 
presence and absence of coexpressed RCC1/PAM.  Interestingly, these functional studies 
revealed that RCC1/PAM could not increase KCC2-RXA cotransporter function, as is the 
case with wild type KCC2 (Figure 24). 
Considering that KCC2-RXA function did not increase, whereas its RNA and 
protein levels did increase, one potential explanation is that KCC2-RXA is not expressed 
in the cell surface to the same extent as wild type KCC2.  Thus, biotinylation experiments 
were used to investigate this idea.  Biotin labeling was first performed on cells transiently 
transfected with KCC2 to mirror the flux experiments previously described.  However, 
weak levels of biotinylated KCC2 signal led to optimization and positive controls of 
biotinylation technique.  These experiments controlling for biotinylation methodology 
were performed in a HEK293FT cell line which stably overexpresses KCC2.  As shown 
in Figure 25A, the biotinylation method used was successful in specifically labeling cell-
surface fractions of transferrin receptor, a widely expressed membrane protein.  However, 
labeling of KCC2 was very inefficient, considering how these cells stably overexpress 
KCC2.  Thus, the aforementioned weak signals of biotinylated KCC2, as depicted in 
Figure 25B, is likely a function of poor incorporation of biotin label on extracellular 
KCC2.  This led to the following studies of NEM-stimulated K-Cl cotransport, as an 
alternative way to further examine the effect of the RXA mutation on KCC2 function. 
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Figure 24.  KCC2, but not the mutant KCC2-RXA, has increased 
activity in the presence of RCC1/PAM. Unidirectional 86Rb+ uptake in 
HEK293 cells was measured after 10 minutes of incubation with 86Rb+. 
p < 0.001 (Tukey post-test) except where indicated.
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Figure 25. Biotinylation of KCC2.
Upper panel: HEK293 cells stably expressing KCC2 were biotinylated in the
presence and absence of a permeabilizing detergent (saponin). Samples were
separated by SDS-PAGE and immunoblotted with anti-KCC2, anti-
transferrin, anti-actin, and anti-GAPDH antibodies. Lower panel: HEK293
cells transiently transfected with KCC2 in the presence and absence of
RCC1/PAM were biotinylated, separated by SDS-PAGE and immunoblotted
with anti-KCC2 and anti-transferrin antibodies.
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N-ethylmaleimide stimulated flux 
NEM is a known activator of KCC2 transport and one possibility is that 
RCC1/PAM and NEM share a common pathway in KCC2 regulation.  Therefore, the 
effect of NEM was tested on wild type KCC2, in the presence and absence of 
RCC1/PAM.  In agreement with the literature, NEM induced activation of KCC2-
mediated K+ uptake in HEK293 cells (Figure 26).   Interestingly, NEM could not further 
stimulate the KCC2-mediated flux induced by RCC1/PAM coexpression. NEM 
stimulation of KCC2-RXA function was also examined.  As shown in Figure 26, KCC2-
RXA was once again demonstrated to be unaffected by RCC1/PAM expression.  KCC2-
RXA function was also unaffected by NEM treatment of the cells.  This lack of NEM 
sensitivity by KCC2-RXA occurred both in the presence and absence of RCC1/PAM 
coexpression.   
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Figure 26. KCC2 mediated flux in the presence and absence of
RCC1/PAM and/or N-ethylmaleimide.
HEK293 cells were transfected with KCC2 alone, KCC2 and RCC1/PAM,
KCC2-RXA alone, or KCC2-RX A and RCC1/PAM. KCC2 uptake activity was
measured using unidirectional Rb uptake after 10 minutes of incubation with
Rb . In +NEM conditions, stimulation was performed for 15 minutes total
(5 minutes prior to Rb incubation, and throughout the 10 minute Rb
incubation). *** = < 0.001 (ANOVA, Tukey post-test).
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Discussion 
KCC2-RXA mutant 
The RXA point mutation was introduced into full-length KCC2 and expressed in 
HEK293 cells.  Quantitation of KCC2 RNA transcript and protein expression showed 
that KCC2-RXA, like wild type KCC2, was subject to RNA upregulation, and thus 
protein upregulation, in the presence of RCC1/PAM.  Coimmunoprecipitation 
experiments with KCC2-RXA showed that this point mutation did not alter the ability of 
full-length KCC2 to coimmunoprecipitate RCC1/PAM.  This suggests that RCC1/PAM 
binds elsewhere on the transporter, as well.  The flux experiments with KCC2-RXA were 
particularly interesting because they demonstrated that KCC2-RXA still retains levels of 
transport activity similar to that of wild type KCC2.  However, unlike wild type KCC2, 
KCC2-RXA activity is unaffected by the coexpression of RCC1/PAM.  Thus, even 
though coimmunoprecipitation experiments show that KCC2-RXA binds elsewhere on 
the cotransporter, the fact that RCC1/PAM does not affect KCC2-RXA function suggests 
that RCC1/PAM does in fact have a functional impact resulting from binding to this 
particular region of KCC2. 
RCC1/PAM seems to have a general effect on transcription in this experimental 
model.  RCC1/PAM causes similar RNA and protein expression effects on both wild type 
KCC2 and mutant KCC2-RXA.  Additionally, RCC1/PAM causes different functional 
effects on wild type KCC2 versus mutant KCC2-RXA.  These facts together suggest that 
the effect of RCC1/PAM on transcription can be set aside when assessing the functional 
role of RCC1/PAM protein binding to the KCC2-CT.  It would however be interesting to 
compare RNA and protein upregulation to assess if the increase in RNA is enough to 
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equal the increase in protein.  It is not likely that this effect on KCC2 transcription would 
carry over to the natural setting of KCC2, as these KCC2 cDNAs are subcloned into 
expression vectors without the KCC2 promoter sequence.   
In summary, these KCC2-RXA experiments suggest RCC1/PAM affects KCC2 in 
multiple ways.  RCC1/PAM causes an RNA upregulation common to both wild type 
KCC2 and KCC2-RXA, which can be set aside to study post-translational modulation via 
RCC1/PAM-KCC2 protein interaction.  KCC2 may bind RCC1/PAM on regions other 
than the KCC2-CT. This binding may or may not account for the fact that KCC2 activity 
increases in the presence of RCC1/PAM, but this has not been determined.  Most 
significantly, it is clearly demonstrated that a single point mutation in the KCC2-CT can 
abolish RCC1/PAM-mediated changes in flux activity.  The present data, in conjunction 
with the experiments described in Chapters II and III, provide compelling evidence that 
RCC1/PAM interacts with KCC2 at this domain on the KCC2-CT, and that this 
interaction on the KCC2-CT has functional consequences.  In conclusion, the mutant 
KCC2-RXA isoform is a useful tool for examining the role of RCC1/PAM interaction 
with KCC2. 
 
PAM in relation to RXR motif function 
Functional experiments with the full-length RXA KCC2 mutant did not show 
increased cotransporter function similar to what would be expected if unmasking an RXR 
motif. Therefore it is questionable whether the RCC1/PAM binding is related to the 
known function of a bona-fide RXR motif. It is clear, however, that the RXR sequence 
and surrounding residues participate in the RCC1/PAM binding, and that altering this 
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motif has functional significance, since unidirectional ion flux experiments demonstrate 
RCC1/PAM coexpression increases K+ uptake by wild type KCC2, but not by the KCC2 
-RXA mutant. 
 
NEM effect on KCC2 and implications for KCC2 and PAM interaction 
NEM is a thiol reactive agent that is known to stimulate KCC function. The most 
convincing evidence suggests that NEM primarily exerts this effect through a 
phosphorylation/dephosphorylation pathway. Indeed, NEM is thought to cause net 
dephosphorylation of an unknown key substrate through kinase inhibition. Subsequent 
dephosphorylation of this substrate, likely by PP1, allows activation of the cotransporter 
(Jennings and Schulz, 1991). Although this evidence does not conclusively rule out a 
direct effect of NEM on KCC2, the fact that NEM has been shown to have opposing 
effects on NKCCs and KCCs would indicate regulation via upstream signaling pathways 
as opposed to direct action on the cotransporters (for review, see (Adragna et al., 2004)). 
The NEM sensitivity of KCC2 and KCC2-RXA in the presence and absence of 
RCC1/PAM was tested to examine if the role of PAM binding to KCC2 might share a 
common pathway as the NEM effect. These studies with NEM, as reported in Figure 26, 
show that wild type KCC2 coexpressed with RCC1/PAM cannot be further stimulated by 
the alkylating agent. Additionally, the KCC2-RXA point mutant also cannot be further 
stimulated by NEM, regardless of whether or not RCC1/PAM is expressed. This indicates 
that this mutated region of the KCC2 carboxyl terminus is necessary for the pathway 
involved in NEM-mediated stimulation of KCC2.  
 101
The specifics on how PAM is intimately involved in the activity of the 
cotransporter, apart from binding to it and affecting NEM stimulation, is yet to be 
determined.  In assessing changes in membrane transporter function, one possibility is 
that RCC1/PAM expression results in an increase in cotransporters present in the cell 
membrane.  If this was the case, NEM stimulation should have an additive effect on 
RCC1/PAM and KCC2 coexpression.  However, NEM stimulation does not have an 
additive effect with RCC1/PAM.  This is particularly important in light of the fact that 
RCC1/PAM also increases overall KCC2 expression. Therefore, this suggests that the 
RCC1/PAM effect is not related to an increased number of transporters in the plasma 
membrane. However, since some change in transporter cell surface expression may make 
up a statistically insignificant portion of the RCC1/PAM-mediated activity changes, there 
is still room for further investigation of KCC2 surface expression studies using different 
extracellular protein labeling techniques.  
This then leads to the conclusion that PAM’s effect on KCC2 occurs when KCC2 
is at the cell membrane.  Other reports on PAM and RCC1 domains pose possible roles 
for PAM.   PAM could directly affect kinase activity or GTP-GDP conversion in the 
vicinity of the cotransporter, as PAM has been shown to inhibit adenylyl cyclase activity 
(Scholich et al., 2001; Gao and Patel, 2005), and RCC1 domains in other proteins have 
been shown to have GTPase activity (Ohtsubo et al., 1989; Bischoff and Ponstingl, 
1991).   
However, the data shown here point strongly to PAM having an effect on KCC2 
activity at the cell membrane via the same phosphoregulatory pathway affected by NEM 
stimulation.  A model of this is illustrated in Figure 27.  HEK293 cells express 
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endogenous PAM (Figure 27, panel A), and the transfected RCC1/PAM fragment 
competes with endogenous PAM for binding on the KCC2 carboxyl terminus (Figure 
27B).  When RCC1/PAM alone binds to wild type KCC2, it independently causes an 
increase in KCC2 activity. There are several possibilities why this may happen.  
RCC1/PAM may cause an allosteric modulation of the cotransporter which endogenous 
PAM does not.  Another possibility is that PAM normally functions as a scaffolding 
protein, recruiting regulatory proteins to the cotransporter.  Thus, when endogenous PAM 
cannot bind the carboxyl terminus of KCC2, as in the case of KCC2-RXA (Figure 27C) 
or when the RCC1/PAM fragment is present (Figure 27B), normal KCC2 regulation 
cannot occur since scaffolded proteins cannot be recruited to KCC2.   
This concept of PAM as a scaffolding protein fits well with the NEM data, in that 
endogenous PAM could also scaffold the kinases or phosphatases which are functionally 
affected by NEM alkylation. As illustrated in Figure 27, NEM stimulation may require 
endogenous PAM recruiting phosphatases or kinases to the vicinity of KCC2 (Figure 
27A). When endogenous PAM cannot bind the carboxyl terminus of KCC2, as in the case 
of KCC2-RXA or when the RCC1/PAM fragment is present, NEM stimulation has no 
effect (Figure 27, panels B and C). Taken altogether, PAM functions as an integral part of 
the same kinase/phosphatase pathway through which NEM exerts its effect. Thus, PAM 
binds to the KCC2 carboxyl terminus as an integral part of the phosphoregulation of 
KCC2 at the cell surface.  
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Figure 27. Model of PAM and KCC2 binding and regulation, and NEM 
stimulation.
Experiments with NEM suggest PAM binding plays a role in 
phosphoregulation of KCC2.  NEM stimulation may involve domains or 
proteins located or bound on the C-terminal side of endogenous full-length 
PAM. PAM is depicted here as a scaffolding protein bringing a regulatory 
kinase (K) and protein phosphatase (PP) to the cotransporter (Panel A).  When 
full-length PAM does not bind to KCC2, either due to blockade by RCC1/PAM 
(Panel B) or mutation of KCC2-CT (Panel C), this interferes with NEM 
stimulation of KCC2 activity. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary of work 
The neuron-specific K+-Cl- cotransporter KCC2 is critical to proper functioning of 
the nervous system, particularly inhibitory signaling through the neurotransmitter GABA.  
Little is known about the regulation of this cotransporter, and even less is known about 
what other proteins interact with KCC2 in order to regulate KCC2-mediated transport 
activity.  Since the carboxyl tail of KCC2 is a cytoplasmic domain, as well as a very large 
portion of the cotransporter, I hypothesized that proteins could potentially interact with 
this region of KCC2 to affect KCC2 function and regulation.  Therefore, I used the 
KCC2-CT in a yeast two-hybrid screen of a mouse brain cDNA library to identify novel 
protein interactors.   
This screen identified Protein Associated with Myc (PAM) as a binding partner 
with the KCC2-CT.  Animal models with mutations of PAM and PAM homologues 
demonstrate that PAM is essential to neurodevelopment.  PAM and KCC2 also share 
overlapping spatial and temporal expression.  This led me to pursue studies of the effect 
of PAM binding to KCC2.  Using the RCC1 domain of PAM (RCC1/PAM) I confirmed 
this newly identified interaction using small-scale yeast two-hybrid, GST pull-down 
assays, and coimmunoprecipitation of coexpressed full-length KCC2 and RCC1/PAM in 
HEK293 cells.   
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Interestingly, I also found that coexpression of RCC1/PAM with KCC2 causes an 
increase in KCC2 activity, protein expression, and RNA levels.  Therefore, in order to 
isolate the effect of RCC1/PAM coexpression on KCC2 at the protein-protein interaction 
level, I characterized the binding site of RCC1/PAM on the KCC2-CT.  After narrowing 
down the RCC1/PAM binding site to a 20 amino acid region of the KCC2-CT, I 
identified an RXR motif in this region of KCC2.  Mutagenesis of this RXR motif, as well 
as the amino acid residue following this motif, are critical to RCC1/PAM binding to this 
region of KCC2, as demonstrated by yeast two-hybrid. 
I introduced the mutated RXR motif, RXA, into full-length KCC2.  Like wild 
type KCC2, KCC2-RXA also has increased RNA and protein levels when coexpressed 
with RCC1/PAM.  Flux experiments showed that KCC2-RXA did not have a 
significantly different level of transport activity than wild type KCC2. However, unlike 
wild type KCC2, KCC2-RXA interestingly does not demonstrate increased activity when 
coexpressed with RCC1/PAM. 
In order to further understand how the RXA mutation affects KCC2 function, I 
tested activity of both the wild type and mutant cotransporter in the presence and absence 
of RCC1/PAM, as well as when stimulated by the known K-Cl transport activator, N-
ethylmaleimide (NEM). NEM most likely exerts its stimulatory effect by causing a net 
dephosphorylation which results in maximal KCC2 activation. These experiments 
presented here show that NEM stimulation does not cause an additive increase in KCC2 
transport when the transporter and RCC1/PAM are coexpressed.  Additionally, KCC2-
RXA activity is not significantly stimulated by addition of NEM in either the presence of 
absence of RCC1/PAM.  Taken together, these data suggest that PAM binds to the KCC2 
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carboxyl terminus as an integral part of the kinase/phosphatase pathway which regulates 
KCC2 activity. 
 
KCC2 and PAM in the neuron 
A critical requirement for the validity of any protein-protein interaction is that 
both proteins be expressed in the same cellular compartment. Since KCC2 subcellular 
localization in neurons is predominantly in postsynaptic areas and cell soma (Gulyas et 
al., 2001; Bartho et al., 2004), it is important that PAM is also expressed in these 
compartments.  Non-mammalian homologues of PAM indicate a presynaptic role of the 
protein, and the recent work on PAM in Magellan mutant mice by Lewcock et al likewise 
suggests a presynaptic role (Lewcock et al., 2007).  However, mammalian PAM has also 
been described as being present throughout neurons (Murthy et al., 2004; Szabadics et al., 
2006).  Thus, it is possible that PAM has numerous roles throughout the cell, as is fitting 
for a protein with many different functional domains, and only the more visually robust 
phenotype of axon outgrowth has been reported.  It would be interesting to conduct a 
detailed study of PAM subcellular localization in the cell soma and dendrites, as was 
done at the growth cone in the studies of neurons from the Magellan mutant mice. 
What could be the role of PAM and KCC2 interaction in the neuron?  The work 
presented here shows that PAM binding is somehow tied into the same regulatory 
pathway as NEM.  NEM is suspected to act as a kinase inhibitor resulting in a net 
dephosphorylation and functional stimulation of KCC2.  It is unknown if in this situation 
the substrate being dephosphorylated is KCC2.  I have demonstrated that NEM 
stimulation of KCC2 cannot occur when RCC1/PAM is expressed, and that NEM cannot 
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stimulate the mutant cotransporter KCC2-RXA. One potential explanation is that 
RCC1/PAM is exerting a dominant-negative effect over endogenous PAM.  Therefore, in 
situations when endogenous PAM cannot bind to KCC2, such as during the coexpression 
of RCC1/PAM, or when the PAM binding site is disrupted on the KCC2 C-terminus, 
KCC2 activation via net phosphorylation by NEM cannot occur.   
Then how does this translate into the native state of the cotransporter, that is, in 
neurons, and without NEM stimulation?  As aforementioned, one possibility is that the 
role of PAM is to act as a scaffolding protein, recruiting protein kinases or phosphatases 
to the cotransporter for dephosphorylation and subsequent activation. Other groups have 
shown that in the axon, PAM works to downregulate kinase activity by ubiquitination of 
a multi-family kinase, specifically the double-leucine-zipper-kinase, or DLK. A global 
model integrating my data with this model is shown in Figure 28.  Perhaps, in the 
dendrites, PAM binding to KCC2 exhibits control of K+-Cl- transport by recruiting of 
phosphoregulatory proteins and ubiquitin-mediated downregulation of a kinase in the 
vicinity of the cotransporter. Downregulation of this unknown kinase could also cause a 
net dephosphorylation and activate the cotransporter.  
In the model presented by Lewcock et al, it is suggested that PAM’s absence from 
the growth cone of developing axons is what allows it to remain fluid and motile 
(Lewcock et al., 2007).  PAM stabilizes microtubules by downregulating DLK.  The 
absence of PAM in the growth cone allows DLK to destabilize microtubules, allowing for 
extension of the axon via the growth cone.  Lewcock et al suggest that, perhaps, when the 
neuron reaches its target, PAM moves to the distal ends of the axon to tag DLK for 
degradation, stabilize microtubules, and thus stabilize the synapse.  Extrapolating this 
 108
idea to PAM’s involvement with KCC2 at the dendrites, perhaps in a similar scenario 
PAM translocates to KCC2, tags a nearby kinase for degradation, thereby enhancing 
KCC2 activity and stabilizing synapses from a post-synaptic perspective via a shift to 
inhibitory GABAergic activity (Figure 28).   In light of the extensive work done on the 
influence of GABA signaling in the developing brain, the involvement of KCC2 and 
PAM in synaptogenesis could be a potentially interesting field of study.  This is 
especially true considering the recently reported interaction between KCC2 and 4.1N 
protein, and the proposed role of KCC2 as a synchronizing factor in synapse 
development. 
The KCC2 and PAM interaction might be involved in processes beyond 
neurodevelopment and synaptogenesis.  For example, as described in Chapters I and III, 
both of these proteins are involved in pain signaling pathways.  A greater understanding 
of PAM modulation of KCC2 activity could lead to novel targets for alleviating chronic 
pain states.  Thus, it is highly possible that the link between KCC2 and PAM may prove 
to be an interesting target for understanding human disease and injury.    
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Figure 28. Model of a possible role for KCC2-PAM binding at the synapse.
This model depicts a dendritic spine and illustrates a potential role of PAM and 
KCC2 binding in neurons.  As depicted on the left, KCC2 function could be 
suppressed by cell signaling molecules, such as an inhibitory kinase (IK, black 
star), and low KCC2 activity leads to a depolarizing GABAergic response. As 
development proceeds, PAM moves into distal projections of the neuron.  In the 
axon (not shown), PAM has been shown to degrade the DLK kinase by tagging 
it for ubiquitination, which in turn leads a solidifying of growth cones and 
development of synapses.  Perhaps at this same timepoint PAM also moves into 
the most distal neuronal projections in the dendrite.  PAM binding to KCC2, as 
depicted on the right, may again lead to kinase inhibition, this time acting on the 
inhibitory kinase suppressing KCC2 function.  By disassociating the inhibitory 
kinase from KCC2, PAM causes a net dephosphorylation which upregulates 
KCC2 activity, thereby allowing the inhibitory GABAergic responses 
characteristic of a mature synapse.
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Future directions 
Future studies are needed to address the role of PAM on KCC2 function in 
neurons. One possibility involves examining the effect of PAM deletion on KCC2 
function and Cl- homeostasis. As mentioned above, at the animal level, deletion of PAM 
results in a phenotype similar to the KCC2 knockout phenotype. A viable mouse 
expressing PAM without the RCC1 domain (or inactive/mutated RCC1 domain) could 
represent a useful model for studying the role of PAM-KCC2 interaction in neurons. 
Another possibility would involve altering PAM expression at the level of the single 
neuron using RNA interference (RNAi). However, as PAM is a large protein with many 
domains, it is possible that its down-regulation by RNAi affects neurons beyond any 
effect related to KCC2. Regardless of whether using cultured cells or whole animal 
models, the studies presented here provide strong evidence that PAM plays a role in 
modulating KCC2 function in neurons, thereby affecting neuronal Cl- concentration and 
GABAA and glycine inhibition. 
 
 111
 
LITERATURE CITED 
 
 
  
Adragna NC, Fulvio MD, Lauf PK (2004) Regulation of K-Cl cotransport: from function 
to genes. J Membr Biol 201:109-137. 
Adragna NC, Zhang J, Di Fulvio M, Lincoln TM, Lauf PK (2002) KCl cotransport 
regulation and protein kinase G in cultured vascular smooth muscle cells. J 
Membr Biol 187:157-165. 
Aguado F, Carmona MA, Pozas E, Aguilo A, Martinez-Guijarro FJ, Alcantara S, Borrell 
V, Yuste R, Ibanez CF, Soriano E (2003) BDNF regulates spontaneous correlated 
activity at early developmental stages by increasing synaptogenesis and 
expression of the K+/Cl- co-transporter KCC2. Development 130:1267-1280. 
Akerman CJ, Cline HT (2006) Depolarizing GABAergic conductances regulate the 
balance of excitation to inhibition in the developing retinotectal circuit in vivo. J 
Neurosci 26:5117-5130. 
Aronica E, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, Gorter JA (2007) 
Differential expression patterns of chloride transporters, Na(+)-K(+)-2Cl(-)-
cotransporter and K(+)-Cl(-)-cotransporter, in epilepsy-associated malformations 
of cortical development. Neuroscience 145:185-196. 
Balakrishnan V, Becker M, Lohrke S, Nothwang HG, Guresir E, Friauf E (2003) 
Expression and function of chloride transporters during development of inhibitory 
neurotransmission in the auditory brainstem. J Neurosci 23:4134-4145. 
Balasubramani M, Day BW, Schoen RE, Getzenberg RH (2006) Altered expression and 
localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and 
high mobility group box 1 protein in the nuclear matrix associated with colon 
cancer. Cancer Res 66:763-769. 
Barmashenko G, Schmidt M, Hoffmann KP (2005) Differences between cation-chloride 
co-transporter functions in the visual cortex of pigmented and albino rats. Eur J 
Neurosci 21:1189-1195. 
 112
Bartho P, Payne JA, Freund TF, Acsady L (2004) Differential distribution of the KCl 
cotransporter KCC2 in thalamic relay and reticular nuclei. Eur J Neurosci 20:965-
975. 
Bauer S, Fujita R, Buraczynska M, Abrahamson M, Ehinger B, Wu W, Falls TJ, 
Andreasson S, Swaroop A (1998) Phenotype of an X-linked retinitis pigmentosa 
family with a novel splice defect in the RPGR gene. Invest Ophthalmol Vis Sci 
39:2470-2474. 
Bergeron MJ, Gagnon E, Caron L, Isenring P (2006) Identification of key functional 
domains in the C terminus of the K+-Cl- cotransporters. J Biol Chem 281:15959-
15969. 
Bischoff FR, Ponstingl H (1991) Catalysis of guanine nucleotide exchange on Ran by the 
mitotic regulator RCC1. Nature 354:80-82. 
Blaesse P, Guillemin I, Schindler J, Schweizer M, Delpire E, Khiroug L, Friauf E, 
Nothwang HG (2006) Oligomerization of KCC2 correlates with development of 
inhibitory neurotransmission. J Neurosci 26:10407-10419. 
Blatch GL, Lassle M (1999) The tetratricopeptide repeat: a structural motif mediating 
protein-protein interactions. Bioessays 21:932-939. 
Bloom AJ, Miller BR, Sanes JR, DiAntonio A (2007) The requirement for Phr1 in CNS 
axon tract formation reveals the corticostriatal boundary as a choice point for 
cortical axons. Genes Dev 21:2593-2606. 
Booth RF, Clark JB (1978) Studies on the mitochondrially bound form of rat brain 
creatine kinase. Biochem J 170:145-151. 
Buraczynska M, Wu W, Fujita R, Buraczynska K, Phelps E, Andreasson S, Bennett J, 
Birch DG, Fishman GA, Hoffman DR, Inana G, Jacobson SG, Musarella MA, 
Sieving PA, Swaroop A (1997) Spectrum of mutations in the RPGR gene that are 
identified in 20% of families with X-linked retinitis pigmentosa. Am J Hum 
Genet 61:1287-1292. 
Burgess RW, Peterson KA, Johnson MJ, Roix JJ, Welsh IC, O'Brien TP (2004) Evidence 
for a conserved function in synapse formation reveals Phr1 as a candidate gene 
for respiratory failure in newborn mice. Mol Cell Biol 24:1096-1105. 
 113
Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze 
R, Markesbery WR, Butterfield DA (2002) Proteomic identification of 
oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase 
BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free 
Radic Biol Med 33:562-571. 
Casula S, Shmukler BE, Wilhelm S, Stuart-Tilley AK, Su W, Chernova MN, Brugnara C, 
Alper SL (2001) A dominant negative mutant of the KCC1 K-Cl cotransporter: 
both N- and C-terminal cytoplasmic domains are required for K-Cl cotransport 
activity. J Biol Chem 276:41870-41878. 
Choi WS, Khurana A, Mathur R, Viswanathan V, Steele DF, Fedida D (2005) Kv1.5 
surface expression is modulated by retrograde trafficking of newly endocytosed 
channels by the dynein motor. Circ Res 97:363-371. 
Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De 
Koninck Y (2003) Trans-synaptic shift in anion gradient in spinal lamina I 
neurons as a mechanism of neuropathic pain. Nature 424:938-942. 
D'Souza J, Hendricks M, Le Guyader S, Subburaju S, Grunewald B, Scholich K, 
Jesuthasan S (2005) Formation of the retinotectal projection requires Esrom, an 
ortholog of PAM (protein associated with Myc). Development 132:247-256. 
Daniels GM, Amara SG (1998) Selective labeling of neurotransmitter transporters at the 
cell surface. Methods Enzymol 296:307-318. 
DeFazio RA, Keros S, Quick MW, Hablitz JJ (2000) Potassium-coupled chloride 
cotransport controls intracellular chloride in rat neocortical pyramidal neurons. J 
Neurosci 20:8069-8076. 
Delpire E (2000) Cation-Chloride Cotransporters in Neuronal Communication. News 
Physiol Sci 15:309-312. 
Delpire E, Gagnon KB (2006) SPAK and OSR1, key kinases involved in the regulation 
of chloride transport. Acta Physiol (Oxf) 187:103-113. 
Delpire E, Gagnon KB (2007) Genome-wide analysis of SPAK/OSR1 binding motifs. 
Physiol Genomics 28:223-231. 
 114
Devon RS, Orban PC, Gerrow K, Barbieri MA, Schwab C, Cao LP, Helm JR, Bissada N, 
Cruz-Aguado R, Davidson TL, Witmer J, Metzler M, Lam CK, Tetzlaff W, 
Simpson EM, McCaffery JM, El-Husseini AE, Leavitt BR, Hayden MR (2006) 
Als2-deficient mice exhibit disturbances in endosome trafficking associated with 
motor behavioral abnormalities. Proc Natl Acad Sci U S A 103:9595-9600. 
DiAntonio A, Haghighi AP, Portman SL, Lee JD, Amaranto AM, Goodman CS (2001) 
Ubiquitination-dependent mechanisms regulate synaptic growth and function. 
Nature 412:449-452. 
Ehnert C, Tegeder I, Pierre S, Birod K, Nguyen HV, Schmidtko A, Geisslinger G, 
Scholich K (2004) Protein associated with Myc (PAM) is involved in spinal 
nociceptive processing. J Neurochem 88:948-957. 
Feng XH, Derynck R (2001) Mammalian two-hybrid assays. Analyzing protein-protein 
interactions in transforming growth factor-beta signaling pathway. Methods Mol 
Biol 177:221-239. 
Gagnon KB, England R, Delpire E (2006) Volume sensitivity of cation-Cl- cotransporters 
is modulated by the interaction of two kinases: Ste20-related proline-alanine-rich 
kinase and WNK4. Am J Physiol Cell Physiol 290:C134-142. 
Gagnon KB, Adragna NC, Fyffe RE, Lauf PK (2007) Characterization of glial cell K-Cl 
cotransport. Cell Physiol Biochem 20:121-130. 
Galanopoulou AS, Moshe SL (2003) Role of sex hormones in the sexually dimorphic 
expression of KCC2 in rat substantia nigra. Exp Neurol 184:1003-1009. 
Ganguly K, Schinder AF, Wong ST, Poo M (2001) GABA itself promotes the 
developmental switch of neuronal GABAergic responses from excitation to 
inhibition. Cell 105:521-532. 
Gao X, Patel TB (2005) Histidine residues 912 and 913 in protein associated with Myc 
are necessary for the inhibition of adenylyl cyclase activity. Mol Pharmacol 
67:42-49. 
Gillen CM, Brill S, Payne JA, Forbush B, 3rd (1996) Molecular cloning and functional 
expression of the K-Cl cotransporter from rabbit, rat, and human. A new member 
of the cation-chloride cotransporter family. J Biol Chem 271:16237-16244. 
 115
Gros-Louis F, Gaspar C, Rouleau GA (2006) Genetics of familial and sporadic 
amyotrophic lateral sclerosis. Biochim Biophys Acta 1762:956-972. 
Gulledge AT, Stuart GJ (2003) Excitatory actions of GABA in the cortex. Neuron 
37:299-309. 
Gulyas AI, Sik A, Payne JA, Kaila K, Freund TF (2001) The KCl cotransporter, KCC2, 
is highly expressed in the vicinity of excitatory synapses in the rat hippocampus. 
Eur J Neurosci 13:2205-2217. 
Guo Q, Xie J, Dang CV, Liu ET, Bishop JM (1998) Identification of a large Myc-binding 
protein that contains RCC1-like repeats. Proc Natl Acad Sci U S A 95:9172-9177. 
Hadano S, Kunita R, Otomo A, Suzuki-Utsunomiya K, Ikeda JE (2007) Molecular and 
cellular function of ALS2/alsin: implication of membrane dynamics in neuronal 
development and degeneration. Neurochem Int 51:74-84. 
Hadano S, Benn SC, Kakuta S, Otomo A, Sudo K, Kunita R, Suzuki-Utsunomiya K, 
Mizumura H, Shefner JM, Cox GA, Iwakura Y, Brown RH, Jr., Ikeda JE (2006) 
Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit 
age-dependent neurological deficits and altered endosome trafficking. Hum Mol 
Genet 15:233-250. 
Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, 
Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA, Kwiatkowski T, 
Hosler BA, Sagie T, Skaug J, Nasir J, Brown RH, Jr., Scherer SW, Rouleau GA, 
Hayden MR, Ikeda JE (2001) A gene encoding a putative GTPase regulator is 
mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29:166-173. 
Haskins WE, Kobeissy FH, Wolper RA, Ottens AK, Kitlen JW, McClung SH, O'Steen 
BE, Chow MM, Pineda JA, Denslow ND, Hayes RL, Wang KK (2005) Rapid 
discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-
capillary liquid chromatography-tandem mass spectrometry. J Neurotrauma 
22:629-644. 
He S, Parapuram SK, Hurd TW, Behnam B, Margolis B, Swaroop A, Khanna H (2008) 
Retinitis Pigmentosa GTPase Regulator (RPGR) protein isoforms in mammalian 
retina: insights into X-linked Retinitis Pigmentosa and associated ciliopathies. 
Vision Res 48:366-376. 
 116
Hegedus T, Aleksandrov A, Cui L, Gentzsch M, Chang XB, Riordan JR (2006) F508del 
CFTR with two altered RXR motifs escapes from ER quality control but its 
channel activity is thermally sensitive. Biochim Biophys Acta 1758:565-572. 
Hekmat-Scafe DS, Lundy MY, Ranga R, Tanouye MA (2006) Mutations in the K+/Cl- 
cotransporter gene kazachoc (kcc) increase seizure susceptibility in Drosophila. J 
Neurosci 26:8943-8954. 
Helms C, Pelsue S, Cao L, Lamb E, Loffredo B, Taillon-Miller P, Herrin B, Burzenski 
LM, Gott B, Lyons BL, Keppler D, Shultz LD, Bowcock AM (2005) The 
Tetratricopeptide repeat domain 7 gene is mutated in flaky skin mice: a model for 
psoriasis, autoimmunity, and anemia. Exp Biol Med (Maywood) 230:659-667. 
Hendricks M, Mathuru AS, Wang H, Silander O, Kee MZ, Jesuthasan S (2008) 
Disruption of Esrom and Ryk identifies the roof plate boundary as an intermediate 
target for commissure formation. Mol Cell Neurosci 37:271-283. 
Hermosilla R, Oueslati M, Donalies U, Schonenberger E, Krause E, Oksche A, Rosenthal 
W, Schulein R (2004) Disease-causing V(2) vasopressin receptors are retained in 
different compartments of the early secretory pathway. Traffic 5:993-1005. 
Hiki K, D'Andrea RJ, Furze J, Crawford J, Woollatt E, Sutherland GR, Vadas MA, 
Gamble JR (1999) Cloning, characterization, and chromosomal location of a 
novel human K+-Cl- cotransporter. J Biol Chem 274:10661-10667. 
Hirosawa M, Nagase T, Ishikawa K, Kikuno R, Nomura N, Ohara O (1999) 
Characterization of cDNA clones selected by the GeneMark analysis from size-
fractionated cDNA libraries from human brain. DNA Res 6:329-336. 
Holtzman D, Meyers R, Khait I, Jensen F (1997) Brain creatine kinase reaction rates and 
reactant concentrations during seizures in developing rats. Epilepsy Res 27:7-11. 
Hubner CA, Stein V, Hermans-Borgmeyer I, Meyer T, Ballanyi K, Jentsch TJ (2001) 
Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early 
synaptic inhibition. Neuron 30:515-524. 
Inoue K, Ueno S, Fukuda A (2004) Interaction of neuron-specific K+-Cl- cotransporter, 
KCC2, with brain-type creatine kinase. FEBS Lett 564:131-135. 
 117
Inoue K, Yamada J, Ueno S, Fukuda A (2006) Brain-type creatine kinase activates 
neuron-specific K+-Cl- co-transporter KCC2. J Neurochem 96:598-608. 
Jacquier A, Buhler E, Schafer MK, Bohl D, Blanchard S, Beclin C, Haase G (2006) 
Alsin/Rac1 signaling controls survival and growth of spinal motoneurons. Ann 
Neurol 60:105-117. 
Jennings ML, Schulz RK (1991) Okadaic acid inhibition of KCl cotransport. Evidence 
that protein dephosphorylation is necessary for activation of transport by either 
cell swelling or N-ethylmaleimide. J Gen Physiol 97:799-817. 
Jennings ML, Adame MF (2001) Direct estimate of 1:1 stoichiometry of K(+)-Cl(-) 
cotransport in rabbit erythrocytes. Am J Physiol Cell Physiol 281:C825-832. 
Jin ZB, Liu XQ, Uchida A, Vervoort R, Morishita K, Hayakawa M, Murakami A, 
Matsumoto N, Niikawa N, Nao-i N (2005) Novel deletion spanning RCC1-like 
domain of RPGR in Japanese X-linked retinitis pigmentosa family. Mol Vis 
11:535-541. 
Kaddurah-Daouk R, Lillie JW, Daouk GH, Green MR, Kingston R, Schimmel P (1990) 
Induction of a cellular enzyme for energy metabolism by transforming domains of 
adenovirus E1a. Mol Cell Biol 10:1476-1483. 
Kakazu Y, Akaike N, Komiyama S, Nabekura J (1999) Regulation of intracellular 
chloride by cotransporters in developing lateral superior olive neurons. J Neurosci 
19:2843-2851. 
Kakazu Y, Uchida S, Nakagawa T, Akaike N, Nabekura J (2000) Reversibility and cation 
selectivity of the K(+)-Cl(-) cotransport in rat central neurons. J Neurophysiol 
84:281-288. 
Karadsheh MF, Delpire E (2001) Neuronal restrictive silencing element is found in the 
KCC2 gene: molecular basis for KCC2-specific expression in neurons. J 
Neurophysiol 85:995-997. 
Kelsch W, Hormuzdi S, Straube E, Lewen A, Monyer H, Misgeld U (2001) Insulin-like 
growth factor 1 and a cytosolic tyrosine kinase activate chloride outward transport 
during maturation of hippocampal neurons. J Neurosci 21:8339-8347. 
 118
Khanna H, Hurd TW, Lillo C, Shu X, Parapuram SK, He S, Akimoto M, Wright AF, 
Margolis B, Williams DS, Swaroop A (2005) RPGR-ORF15, which is mutated in 
retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport 
proteins. J Biol Chem 280:33580-33587. 
Kristensen O, Guenat S, Dar I, Allaman-Pillet N, Abderrahmani A, Ferdaoussi M, Roduit 
R, Maurer F, Beckmann JS, Kastrup JS, Gajhede M, Bonny C (2006) A unique 
set of SH3-SH3 interactions controls IB1 homodimerization. EMBO J 25:785-
797. 
Kunita R, Otomo A, Mizumura H, Suzuki-Utsunomiya K, Hadano S, Ikeda JE (2007) 
The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-
activated endocytosis. J Biol Chem 282:16599-16611. 
Kuzhikandathil EV, Molloy GR (1994) Transcription of the brain creatine kinase gene in 
glial cells is modulated by cyclic AMP-dependent protein kinase. J Neurosci Res 
39:70-82. 
Kuzhikandathil EV, Molloy GR (1999) Proximal promoter of the rat brain creatine kinase 
gene lacks a consensus CRE element but is essential for the cAMP-mediated 
increased transcription in glioblastoma cells. J Neurosci Res 56:371-385. 
Lai C, Xie C, McCormack SG, Chiang HC, Michalak MK, Lin X, Chandran J, Shim H, 
Shimoji M, Cookson MR, Huganir RL, Rothstein JD, Price DL, Wong PC, Martin 
LJ, Zhu JJ, Cai H (2006) Amyotrophic lateral sclerosis 2-deficiency leads to 
neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA 
receptor trafficking. J Neurosci 26:11798-11806. 
Lamb JR, Tugendreich S, Hieter P (1995) Tetratrico peptide repeat interactions: to TPR 
or not to TPR? Trends Biochem Sci 20:257-259. 
Lauf PK, Theg BE (1980) A chloride dependent K+ flux induced by N-ethylmaleimide in 
genetically low K+ sheep and goat erythrocytes. Biochem Biophys Res Comm 
70:221-242. 
Lauf PK, Adragna NC (2000) K-Cl cotransport: properties and molecular mechanism. 
Cell Physiol Biochem 10:341-354. 
 119
Lauf PK, Adragna NC, Dupre N, Bouchard JP, Rouleau GA (2006) K-Cl cotransport in 
red blood cells from patients with KCC3 isoform mutants. Biochem Cell Biol 
84:1034-1044. 
Lauf PK, Bauer J, Adragna NC, Fujise H, Zade-Oppen AM, Ryu KH, Delpire E (1992) 
Erythrocyte K-Cl cotransport: properties and regulation. Am J Physiol 263:C917-
932. 
Le Guyader S, Maier J, Jesuthasan S (2005) Esrom, an ortholog of PAM (protein 
associated with c-myc), regulates pteridine synthesis in the zebrafish. Dev Biol 
277:378-386. 
Leupen SM, Tobet SA, Crowley WF, Jr., Kaila K (2003) Heterogeneous expression of 
the potassium-chloride cotransporter KCC2 in gonadotropin-releasing hormone 
neurons of the adult mouse. Endocrinology 144:3031-3036. 
Lewcock JW, Genoud N, Lettieri K, Pfaff SL (2007) The Ubiquitin Ligase Phr1 
Regulates Axon Outgrowth through Modulation of Microtubule Dynamics. 
Neuron 56:604-620. 
Li H, Khirug S, Cai C, Ludwig A, Blaesse P, Kolikova J, Afzalov R, Coleman SK, Lauri 
S, Airaksinen MS, Keinanen K, Khiroug L, Saarma M, Kaila K, Rivera C (2007) 
KCC2 Interacts with the Dendritic Cytoskeleton to Promote Spine Development. 
Neuron 56:1019-1033. 
Linari M, Ueffing M, Manson F, Wright A, Meitinger T, Becker J (1999) The retinitis 
pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod 
cyclic GMP phosphodiesterase. Proc Natl Acad Sci U S A 96:1315-1320. 
Lu J, Karadsheh M, Delpire E (1999) Developmental regulation of the neuronal-specific 
isoform of K-Cl cotransporter KCC2 in postnatal rat brains. J Neurobiol 39:558-
568. 
Mahadevan LC, Whatley SA, Leung TK, Lim L (1984) The brain isoform of a key ATP-
regulating enzyme, creatine kinase, is a phosphoprotein. Biochem J 222:139-144. 
Margeta-Mitrovic M, Jan YN, Jan LY (2000) A trafficking checkpoint controls 
GABA(B) receptor heterodimerization. Neuron 27:97-106. 
 120
McCabe BD, Hom S, Aberle H, Fetter RD, Marques G, Haerry TE, Wan H, O'Connor 
MB, Goodman CS, Haghighi AP (2004) Highwire regulates presynaptic BMP 
signaling essential for synaptic growth. Neuron 41:891-905. 
McCarthy MM, Auger AP, Perrot-Sinal TS (2002) Getting excited about GABA and sex 
differences in the brain. Trends Neurosci 25:307-312. 
Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A, Edgar A, Carvalho MR, 
Achatz H, Hellebrand H, Lennon A, Migliaccio C, Porter K, Zrenner E, Bird A, 
Jay M, Lorenz B, Wittwer B, D'Urso M, Meitinger T, Wright A (1996) A gene 
(RPGR) with homology to the RCC1 guanine nucleotide exchange factor is 
mutated in X-linked retinitis pigmentosa (RP3). Nat Genet 13:35-42. 
Mercado A, Broumand V, Zandi-Nejad K, Enck AH, Mount DB (2006) A C-terminal 
domain in KCC2 confers constitutive K+-Cl- cotransport. J Biol Chem 281:1016-
1026. 
Miano MG, Testa F, Strazzullo M, Trujillo M, De Bernardo C, Grammatico B, Simonelli 
F, Mangino M, Torrente I, Ruberto G, Beneyto M, Antinolo G, Rinaldi E, 
Danesino C, Ventruto V, D'Urso M, Ayuso C, Baiget M, Ciccodicola A (1999) 
Mutation analysis of the RPGR gene reveals novel mutations in south European 
patients with X-linked retinitis pigmentosa. Eur J Hum Genet 7:687-694. 
Miletic G, Miletic V (2007) Loose ligation of the sciatic nerve is associated with TrkB 
receptor-dependent decreases in KCC2 protein levels in the ipsilateral spinal 
dorsal horn. Pain. 
Mockli N, Deplazes A, Hassa PO, Zhang Z, Peter M, Hottiger MO, Stagljar I, Auerbach 
D (2007) Yeast split-ubiquitin-based cytosolic screening system to detect 
interactions between transcriptionally active proteins. Biotechniques 42:725-730. 
Moore-Hoon ML, Turner RJ (2000) The structural unit of the secretory Na+-K+-2Cl- 
cotransporter (NKCC1) is a homodimer. Biochemistry 39:3718-3724. 
Mount DB, Mercado A, Song L, Xu J, George AL, Jr., Delpire E, Gamba G (1999) 
Cloning and characterization of KCC3 and KCC4, new members of the cation-
chloride cotransporter gene family. J Biol Chem 274:16355-16362. 
 121
Munoz A, Mendez P, DeFelipe J, Alvarez-Leefmans FJ (2007) Cation-chloride 
cotransporters and GABA-ergic innervation in the human epileptic hippocampus. 
Epilepsia 48:663-673. 
Murthy V, Han S, Beauchamp RL, Smith N, Haddad LA, Ito N, Ramesh V (2004) Pam 
and its ortholog highwire interact with and may negatively regulate the 
TSC1.TSC2 complex. J Biol Chem 279:1351-1358. 
Nabekura J, Ueno T, Okabe A, Furuta A, Iwaki T, Shimizu-Okabe C, Fukuda A, Akaike 
N (2002) Reduction of KCC2 expression and GABAA receptor-mediated 
excitation after in vivo axonal injury. J Neurosci 22:4412-4417. 
Neidhardt J, Glaus E, Barthelmes D, Zeitz C, Fleischhauer J, Berger W (2007) 
Identification and characterization of a novel RPGR isoform in human retina. 
Hum Mutat 28:797-807. 
Nomura H, Sakai A, Nagano M, Umino M, Suzuki H (2006) Expression changes of 
cation chloride cotransporters in the rat spinal cord following intraplantar 
formalin. Neurosci Res 56:435-440. 
Nunez JL, McCarthy MM (2007) Evidence for an extended duration of GABA-mediated 
excitation in the developing male versus female hippocampus. Dev Neurobiol 
67:1879-1890. 
Ohtsubo M, Okazaki H, Nishimoto T (1989) The RCC1 protein, a regulator for the onset 
of chromosome condensation locates in the nucleus and binds to DNA. J Cell Biol 
109:1389-1397. 
Otomo A, Hadano S, Okada T, Mizumura H, Kunita R, Nishijima H, Showguchi-Miyata 
J, Yanagisawa Y, Kohiki E, Suga E, Yasuda M, Osuga H, Nishimoto T, Narumiya 
S, Ikeda JE (2003) ALS2, a novel guanine nucleotide exchange factor for the 
small GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet 
12:1671-1687. 
Palma E, Amici M, Sobrero F, Spinelli G, Di Angelantonio S, Ragozzino D, Mascia A, 
Scoppetta C, Esposito V, Miledi R, Eusebi F (2006) Anomalous levels of Cl- 
transporters in the hippocampal subiculum from temporal lobe epilepsy patients 
make GABA excitatory. Proc Natl Acad Sci U S A 103:8465-8468. 
 122
Payne JA (1997) Functional characterization of the neuronal-specific K-Cl cotransporter: 
implications for [K+]o regulation. Am J Physiol 273:C1516-1525. 
Payne JA, Stevenson TJ, Donaldson LF (1996) Molecular characterization of a putative 
K-Cl cotransporter in rat brain. A neuronal-specific isoform. J Biol Chem 
271:16245-16252. 
Pearson MM, Lu J, Mount DB, Delpire E (2001) Localization of the K(+)-Cl(-) 
cotransporter, KCC3, in the central and peripheral nervous systems: expression in 
the choroid plexus, large neurons and white matter tracts. Neuroscience 103:481-
491. 
Perrot-Sinal TS, Sinal CJ, Reader JC, Speert DB, McCarthy MM (2007) Sex differences 
in the chloride cotransporters, NKCC1 and KCC2, in the developing 
hypothalamus. J Neuroendocrinol 19:302-308. 
Peterson KA, King BL, Hagge-Greenberg A, Roix JJ, Bult CJ, O'Brien TP (2002) 
Functional and comparative genomic analysis of the piebald deletion region of 
mouse chromosome 14. Genomics 80:172-184. 
Piechotta K, Lu J, Delpire E (2002) Cation chloride cotransporters interact with the 
stress-related kinases Ste20-related proline-alanine-rich kinase (SPAK) and 
oxidative stress response 1 (OSR1). J Biol Chem 277:50812-50819. 
Piechotta K, Garbarini N, England R, Delpire E (2003) Characterization of the interaction 
of the stress kinase SPAK with the Na+-K+-2Cl- cotransporter in the nervous 
system: evidence for a scaffolding role of the kinase. J Biol Chem 278:52848-
52856. 
Pierre SC, Hausler J, Birod K, Geisslinger G, Scholich K (2004) PAM mediates sustained 
inhibition of cAMP signaling by sphingosine-1-phosphate. Embo J 23:3031-3040. 
Pramfalk C, Lanner J, Andersson M, Danielsson E, Kaiser C, Renstrom IM, Warolen M, 
James SR (2004) Insulin receptor activation and down-regulation by cationic lipid 
transfection reagents. BMC Cell Biol 5:7. 
Price TJ, Cervero F, de Koninck Y (2005) Role of cation-chloride-cotransporters (CCC) 
in pain and hyperalgesia. Curr Top Med Chem 5:547-555. 
 123
Race JE, Makhlouf FN, Logue PJ, Wilson FH, Dunham PB, Holtzman EJ (1999) 
Molecular cloning and functional characterization of KCC3, a new K-Cl 
cotransporter. Am J Physiol 277:C1210-1219. 
Reid KH, Guo SZ, Iyer VG (2000) Agents which block potassium-chloride cotransport 
prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. 
Brain Res 864:134-137. 
Reid KH, Li GY, Payne RS, Schurr A, Cooper NG (2001) The mRNA level of the 
potassium-chloride cotransporter KCC2 covaries with seizure susceptibility in 
inferior colliculus of the post-ischemic audiogenic seizure-prone rat. Neurosci 
Lett 308:29-32. 
Renault L, Nassar N, Vetter I, Becker J, Klebe C, Roth M, Wittinghofer A (1998) The 1.7 
A crystal structure of the regulator of chromosome condensation (RCC1) reveals 
a seven-bladed propeller. Nature 392:97-101. 
Rivera C, Voipio J, Kaila K (2005) Two developmental switches in GABAergic 
signalling: the K+-Cl- cotransporter KCC2 and carbonic anhydrase CAVII. J 
Physiol 562:27-36. 
Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, Pirvola U, Saarma 
M, Kaila K (1999) The K+/Cl- co-transporter KCC2 renders GABA 
hyperpolarizing during neuronal maturation. Nature 397:251-255. 
Rivera C, Voipio J, Thomas-Crusells J, Li H, Emri Z, Sipila S, Payne JA, Minichiello L, 
Saarma M, Kaila K (2004) Mechanism of activity-dependent downregulation of 
the neuron-specific K-Cl cotransporter KCC2. J Neurosci 24:4683-4691. 
Rivera C, Li H, Thomas-Crusells J, Lahtinen H, Viitanen T, Nanobashvili A, Kokaia Z, 
Airaksinen MS, Voipio J, Kaila K, Saarma M (2002) BDNF-induced TrkB 
activation down-regulates the K+-Cl- cotransporter KCC2 and impairs neuronal 
Cl- extrusion. J Cell Biol 159:747-752. 
Roepman R, Bernoud-Hubac N, Schick DE, Maugeri A, Berger W, Ropers HH, Cremers 
FP, Ferreira PA (2000) The retinitis pigmentosa GTPase regulator (RPGR) 
interacts with novel transport-like proteins in the outer segments of rod 
photoreceptors. Hum Mol Genet 9:2095-2105. 
 124
Roos J, Kelly RB (1998) Dap160, a neural-specific Eps15 homology and multiple SH3 
domain-containing protein that interacts with Drosophila dynamin. J Biol Chem 
273:19108-19119. 
Sandrock B, Tirode F, Egly JM (2001) Three-hybrid screens. Inducible third-party 
systems. Methods Mol Biol 177:271-289. 
Santos TM, Han S, Bowser M, Sazani K, Beauchamp RL, Murthy V, Bhide PG, Ramesh 
V (2006) Alternative splicing in protein associated with Myc (Pam) influences its 
binding to c-Myc. J Neurosci Res 83:222-232. 
Schaefer AM, Hadwiger GD, Nonet ML (2000) rpm-1, a conserved neuronal gene that 
regulates targeting and synaptogenesis in C. elegans. Neuron 26:345-356. 
Scholich K, Pierre S, Patel TB (2001) Protein associated with Myc (PAM) is a potent 
inhibitor of adenylyl cyclases. J Biol Chem 276:47583-47589. 
Scott DB, Blanpied TA, Swanson GT, Zhang C, Ehlers MD (2001) An NMDA receptor 
ER retention signal regulated by phosphorylation and alternative splicing. J 
Neurosci 21:3063-3072. 
Sheng M, Kim E (2000) The Shank family of scaffold proteins. J Cell Sci 113 ( Pt 
11):1851-1856. 
Simard CF, Bergeron MJ, Cotton-Frenette R, Carpentier GA, Pelchat ME, Caron L, 
Isenring P (2007) Homooligomeric and heterooligomeric associations between K-
Cl cotransporter isoforms and between K-Cl and Na-K-Cl cotransporters. J Biol 
Chem. 
Somer H, Kaste M, Troupp H, Konttinen A (1975) Brain creatine kinase in blood after 
acute brain injury. J Neurol Neurosurg Psychiatry 38:572-576. 
Stein V, Hermans-Borgmeyer I, Jentsch TJ, Hubner CA (2004) Expression of the KCl 
cotransporter KCC2 parallels neuronal maturation and the emergence of low 
intracellular chloride. J Comp Neurol 468:57-64. 
Strange K, Singer TD, Morrison R, Delpire E (2000) Dependence of KCC2 K-Cl 
cotransporter activity on a conserved carboxy terminus tyrosine residue. Am J 
Physiol Cell Physiol 279:C860-867. 
 125
Streck EL, Amboni G, Scaini G, Di-Pietro PB, Rezin GT, Valvassori SS, Luz G, 
Kapczinski F, Quevedo J (2008) Brain creatine kinase activity in an animal model 
of mania. Life Sci 82:424-429. 
Szabadics J, Varga C, Molnar G, Olah S, Barzo P, Tamas G (2006) Excitatory effect of 
GABAergic axo-axonic cells in cortical microcircuits. Science 311:233-235. 
Thaminy S, Miller J, Stagljar I (2004) The split-ubiquitin membrane-based yeast two-
hybrid system. Methods Mol Biol 261:297-312. 
Tian L, Chen L, McClafferty H, Sailer CA, Ruth P, Knaus HG, Shipston MJ (2006) A 
noncanonical SH3 domain binding motif links BK channels to the actin 
cytoskeleton via the SH3 adapter cortactin. FASEB J 20:2588-2590. 
Toyoda H, Ohno K, Yamada J, Ikeda M, Okabe A, Sato K, Hashimoto K, Fukuda A 
(2003) Induction of NMDA and GABAA receptor-mediated Ca2+ oscillations 
with KCC2 mRNA downregulation in injured facial motoneurons. J Neurophysiol 
89:1353-1362. 
Tudor EL, Perkinton MS, Schmidt A, Ackerley S, Brownlees J, Jacobsen NJ, Byers HL, 
Ward M, Hall A, Leigh PN, Shaw CE, McLoughlin DM, Miller CC (2005) 
ALS2/Alsin regulates Rac-PAK signaling and neurite outgrowth. J Biol Chem 
280:34735-34740. 
Ueno T, Okabe A, Akaike N, Fukuda A, Nabekura J (2002) Diversity of neuron-specific 
K+-Cl- cotransporter expression and inhibitory postsynaptic potential depression 
in rat motoneurons. J Biol Chem 277:4945-4950. 
Uvarov P, Pruunsild P, Timmusk T, Airaksinen MS (2005) Neuronal K+/Cl- co-
transporter (KCC2) transgenes lacking neurone restrictive silencer element 
recapitulate CNS neurone-specific expression and developmental up-regulation of 
endogenous KCC2 gene. J Neurochem 95:1144-1155. 
Uvarov P, Ludwig A, Markkanen M, Rivera C, Airaksinen MS (2006) Upregulation of 
the neuron-specific K+/Cl- cotransporter expression by transcription factor early 
growth response 4. J Neurosci 26:13463-13473. 
Uvarov P, Ludwig A, Markkanen M, Pruunsild P, Kaila K, Delpire E, Timmusk T, 
Rivera C, Airaksinen MS (2007) A novel N-terminal isoform of the neuron-
specific K-Cl cotransporter KCC2. J Biol Chem 282:30570-30576. 
 126
Van Criekinge W, Beyaert R (1999) Yeast Two-Hybrid: State of the Art. Biol Proced 
Online 2:1-38. 
Vardi N, Zhang LL, Payne JA, Sterling P (2000) Evidence that different cation chloride 
cotransporters in retinal neurons allow opposite responses to GABA. J Neurosci 
20:7657-7663. 
Vervoort R, Wright AF (2002) Mutations of RPGR in X-linked retinitis pigmentosa 
(RP3). Hum Mutat 19:486-500. 
Vervoort R, Lennon A, Bird AC, Tulloch B, Axton R, Miano MG, Meindl A, Meitinger 
T, Ciccodicola A, Wright AF (2000) Mutational hot spot within a new RPGR 
exon in X-linked retinitis pigmentosa. Nat Genet 25:462-466. 
Vivithanaporn P, Yan S, Swanson GT (2006) Intracellular trafficking of KA2 kainate 
receptors mediated by interactions with coatomer protein complex I (COPI) and 
14-3-3 chaperone systems. J Biol Chem 281:15475-15484. 
Wan HI, DiAntonio A, Fetter RD, Bergstrom K, Strauss R, Goodman CS (2000) 
Highwire regulates synaptic growth in Drosophila. Neuron 26:313-329. 
White RA, McNulty SG, Nsumu NN, Boydston LA, Brewer BP, Shimizu K (2005) 
Positional cloning of the Ttc7 gene required for normal iron homeostasis and 
mutated in hea and fsn anemia mice. Genomics 85:330-337. 
Williams JR, Sharp JW, Kumari VG, Wilson M, Payne JA (1999) The neuron-specific K-
Cl cotransporter, KCC2. Antibody development and initial characterization of the 
protein. J Biol Chem 274:12656-12664. 
Willis D, Parameswaran B, Shen W, Molloy GR (1999) Conditions providing enhanced 
transfection efficiency in rat pheochromocytoma PC12 cells permit analysis of the 
activity of the far-upstream and proximal promoter of the brain creatine kinase 
gene. J Neurosci Methods 92:3-13. 
Woo NS, Lu J, England R, McClellan R, Dufour S, Mount DB, Deutch AY, Lovinger 
DM, Delpire E (2002) Hyperexcitability and epilepsy associated with disruption 
of the mouse neuronal-specific K-Cl cotransporter gene. Hippocampus 12:258-
268. 
 127
Wu C, Wairkar YP, Collins CA, DiAntonio A (2005) Highwire function at the 
Drosophila neuromuscular junction: spatial, structural, and temporal 
requirements. J Neurosci 25:9557-9566. 
Xu Z, Kukekov NV, Greene LA (2003) POSH acts as a scaffold for a multiprotein 
complex that mediates JNK activation in apoptosis. Embo J 22:252-261. 
Yamanaka K, Vande Velde C, Eymard-Pierre E, Bertini E, Boespflug-Tanguy O, 
Cleveland DW (2003) Unstable mutants in the peripheral endosomal membrane 
component ALS2 cause early-onset motor neuron disease. Proc Natl Acad Sci U 
S A 100:16041-16046. 
Yang H, Scholich K, Poser S, Storm DR, Patel TB, Goldowitz D (2002) Developmental 
expression of PAM (protein associated with MYC) in the rodent brain. Brain Res 
Dev Brain Res 136:35-42. 
Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, 
Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance 
M, Hentati F, Siddique T (2001) The gene encoding alsin, a protein with three 
guanine-nucleotide exchange factor domains, is mutated in a form of recessive 
amyotrophic lateral sclerosis. Nat Genet 29:160-165. 
Yuan H, Michelsen K, Schwappach B (2003) 14-3-3 dimers probe the assembly status of 
multimeric membrane proteins. Curr Biol 13:638-646. 
Zerangue N, Schwappach B, Jan YN, Jan LY (1999) A new ER trafficking signal 
regulates the subunit stoichiometry of plasma membrane K(ATP) channels. 
Neuron 22:537-548. 
Zhao J, Schmieg FI, Simmons DT, Molloy GR (1994) Mouse p53 represses the rat brain 
creatine kinase gene but activates the rat muscle creatine kinase gene. Mol Cell 
Biol 14:8483-8492. 
Zhen M, Huang X, Bamber B, Jin Y (2000) Regulation of presynaptic terminal 
organization by C. elegans RPM-1, a putative guanine nucleotide exchanger with 
a RING-H2 finger domain. Neuron 26:331-343. 
Zhu L, Lovinger D, Delpire E (2005) Cortical neurons lacking KCC2 expression show 
impaired regulation of intracellular chloride. J Neurophysiol 93:1557-1568. 
 
